메뉴 건너뛰기




Volumn 1, Issue 4, 2011, Pages 325-347

Treatment-refractory schizophrenia: What is it and what has been done about it?

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMISULPRIDE; AMITRIPTYLINE; ARIPIPRAZOLE; BENZATROPINE MESILATE; CELECOXIB; CHLORPROMAZINE; CITALOPRAM; CLOZAPINE; DESIPRAMINE; ESCITALOPRAM; FLUOXETINE; FLUPHENAZINE; FLUPHENAZINE DECANOATE; FLUVOXAMINE; HALOPERIDOL; IMIPRAMINE; LEVOMEPROMAZINE; MIANSERIN; MIRTAZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; QUETIAPINE; REBOXETINE; RISPERIDONE; RITANSERIN; SULPIRIDE; UNINDEXED DRUG; ZIPRASIDONE;

EID: 81955162427     PISSN: 17582008     EISSN: 17582016     Source Type: Journal    
DOI: 10.2217/npy.11.35     Document Type: Review
Times cited : (8)

References (258)
  • 1
    • 0035666578 scopus 로고    scopus 로고
    • The early stages of schizophrenia: Speculations on pathogenesis, pathophysiology, and therapeutic approaches
    • DOI 10.1016/S0006-3223(01)01303-8, PII S0006322301013038
    • Lieberman JA, Perkins D, Belger A et al. The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biol. Psychiatry 50(11), 884-897 (2001). (Pubitemid 34023591)
    • (2001) Biological Psychiatry , vol.50 , Issue.11 , pp. 884-897
    • Lieberman, J.A.1    Perkins, D.2    Belger, A.3    Chakos, M.4    Jarskog, F.5    Boteva, K.6    Gilmore, J.7
  • 3
    • 26444464824 scopus 로고    scopus 로고
    • Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: A critical review and meta-analysis
    • Perkins DO, Gu H, Boteva K, Lieberman JA. Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. Am. J. Psychiatry 162(9), 1744-1746 (2005).
    • (2005) Am. J. Psychiatry , vol.162 , Issue.9 , pp. 1744-1746
    • Perkins, D.O.1    Gu, H.2    Boteva, K.3    Lieberman, J.A.4
  • 4
    • 0023812652 scopus 로고
    • Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine
    • Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry 45(9), 789-796 (1988).
    • (1988) Arch. Gen. Psychiatry , vol.45 , Issue.9 , pp. 789-796
    • Kane, J.1    Honigfeld, G.2    Singer, J.3    Meltzer, H.4
  • 6
    • 0023606101 scopus 로고
    • The positive and negative syndrome scale (PANSS) for schizophrenia
    • Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 13(2), 261-276 (1987). (Pubitemid 18039085)
    • (1987) Schizophrenia Bulletin , vol.13 , Issue.2 , pp. 261-276
    • Kay, S.R.1    Fiszbein, A.2    Opler, L.A.3
  • 7
    • 2442545310 scopus 로고    scopus 로고
    • Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia
    • Lindenmayer JP, Czobor P, Volavka J et al. Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia. J. Clin. Psychiatry 65(4), 551-556 (2004).
    • (2004) J. Clin. Psychiatry , vol.65 , Issue.4 , pp. 551-556
    • Lindenmayer, J.P.1    Czobor, P.2    Volavka, J.3
  • 8
    • 1642367338 scopus 로고    scopus 로고
    • Managing treatment-resistant schizophrenia: Evidence from randomized clinical trials
    • Citrome L, Bilder RM, Volavka J. Managing treatment-resistant schizophrenia: evidence from randomized clinical trials. J. Psychiatr. Pract. 8(4), 205-215 (2002).
    • (2002) J. Psychiatr. Pract. , vol.8 , Issue.4 , pp. 205-215
    • Citrome, L.1    Bilder, R.M.2    Volavka, J.3
  • 9
    • 47149103828 scopus 로고    scopus 로고
    • Heterogeneity of violence in schizophrenia and implications for long-term treatment
    • DOI 10.1111/j.1742-1241.2008.01797.x
    • Volavka J, Citrome L. Heterogeneity of violence in schizophrenia and implications for long-term treatment. Int. J. Clin. Pract. 62(8), 1237-1245 (2008). (Pubitemid 351977615)
    • (2008) International Journal of Clinical Practice , vol.62 , Issue.8 , pp. 1237-1245
    • Volavka, J.1    Citrome, L.2
  • 10
    • 79951579967 scopus 로고    scopus 로고
    • Measuring psychosocial outcomes in schizophrenia patients
    • Figueira ML, Brissos S. Measuring psychosocial outcomes in schizophrenia patients. Curr. Opin. Psychiatry 24(2), 91-99 (2011).
    • (2011) Curr. Opin. Psychiatry , vol.24 , Issue.2 , pp. 91-99
    • Figueira, M.L.1    Brissos, S.2
  • 11
    • 0034022621 scopus 로고    scopus 로고
    • Development, reliability and acceptability of a new version of the DSM- IV Social Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning
    • DOI 10.1034/j.1600-0447.2000.101004323.x
    • Morosini PL, Magliano L, Brambilla L, Ugolini S, Pioli R. Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr. Scand. 101(4), 323-329 (2000). (Pubitemid 30173584)
    • (2000) Acta Psychiatrica Scandinavica , vol.101 , Issue.4 , pp. 323-329
    • Morosini, P.-L.1    Magliano, L.2    Brambilla, L.3    Ugolini, S.4    Pioli, R.5
  • 12
    • 58249135027 scopus 로고    scopus 로고
    • Development and psychometric performance of the schizophrenia objective functioning instrument: An interviewer administered measure of function
    • Kleinman L, Lieberman J, Dube S et al. Development and psychometric performance of the schizophrenia objective functioning instrument: an interviewer administered measure of function. Schizophr. Res. 107(2-3), 275-285 (2009).
    • (2009) Schizophr. Res. , vol.107 , Issue.2-3 , pp. 275-285
    • Kleinman, L.1    Lieberman, J.2    Dube, S.3
  • 13
    • 0035222398 scopus 로고    scopus 로고
    • UCSD Performance-Based Skills Assessment: Development of a New Measure of Everyday Functioning for Severely Mentally Ill Adults
    • Patterson TL, Goldman S, McKibbin CL, Hughs T, Jeste DV. UCSD performance-based skills assessment: development of a new measure of everyday functioning for severely mentally ill adults. Schizophr. Bull. 27(2), 235-245 (2001). (Pubitemid 33644299)
    • (2001) Schizophrenia Bulletin , vol.27 , Issue.2 , pp. 235-245
    • Patterson, T.L.1    Goldman, S.2    McKibbin, C.L.3    Hughs, T.4    Jeste, D.V.5
  • 16
    • 24344478615 scopus 로고    scopus 로고
    • Pharmacological treatments for first-episode schizophrenia
    • DOI 10.1093/schbul/sbi032
    • Robinson DG, Woerner MG, Delman HM, Kane JM. Pharmacological treatments for first-episode schizophrenia. Schizophr. Bull. 31(3), 705-722 (2005). (Pubitemid 41253320)
    • (2005) Schizophrenia Bulletin , vol.31 , Issue.3 , pp. 705-722
    • Robinson, D.G.1    Woerner, M.G.2    Delman, H.M.3    Kane, J.M.4
  • 17
    • 0036773689 scopus 로고    scopus 로고
    • Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: A comprehensive review of recent literature
    • Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J. Clin. Psychiatry 63(10), 892-909 (2002). (Pubitemid 35231730)
    • (2002) Journal of Clinical Psychiatry , vol.63 , Issue.10 , pp. 892-909
    • Lacro, J.P.1    Dunn, L.B.2    Dolder, C.R.3    Leckband, S.G.4    Jeste, D.V.5
  • 18
    • 0036942527 scopus 로고    scopus 로고
    • Predictors of noncompliance in patients with schizophrenia
    • Perkins DO. Predictors of noncompliance in patients with schizophrenia. J. Clin. Psychiatry 63(12), 1121-1128 (2002). (Pubitemid 36084056)
    • (2002) Journal of Clinical Psychiatry , vol.63 , Issue.12 , pp. 1121-1128
    • Perkins, D.O.1
  • 19
    • 35649028046 scopus 로고    scopus 로고
    • Correlates and long-term consequences of poor insight in patients with schizophrenia. A systematic review
    • DOI 10.1093/schbul/sbm002
    • Lincoln TM, Lüllmann E, Rief W. Correlates and long-term consequences of poor insight in patients with schizophrenia. A systematic review. Schizophr. Bull. 33(6), 1324-1342 (2007). (Pubitemid 350022767)
    • (2007) Schizophrenia Bulletin , vol.33 , Issue.6 , pp. 1324-1342
    • Lincoln, T.M.1    Lullmann, E.2    Rief, W.3
  • 20
    • 0025226205 scopus 로고
    • Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) study
    • Regier DA, Farmer ME, Rae DS et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 264(19), 2511-2518 (1990).
    • (1990) JAMA , vol.264 , Issue.19 , pp. 2511-2518
    • Regier, D.A.1    Farmer, M.E.2    Rae, D.S.3
  • 21
    • 0036735166 scopus 로고    scopus 로고
    • Optimal dosing of atypical antipsychotics in adults: A review of the current evidence
    • Citrome L, Volavka J. Optimal dosing of atypical antipsychotics in adults: a review of the current evidence. Harv. Rev. Psychiatry 10(5), 280-291 (2002).
    • (2002) Harv. Rev. Psychiatry , vol.10 , Issue.5 , pp. 280-291
    • Citrome, L.1    Volavka, J.2
  • 22
    • 58049157203 scopus 로고    scopus 로고
    • Second-generation versus first-generation antipsychotic drugs for schizophrenia: A meta-analysis
    • Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373(9657), 31-41 (2009).
    • (2009) Lancet , vol.373 , Issue.9657 , pp. 31-41
    • Leucht, S.1    Corves, C.2    Arbter, D.3    Engel, R.R.4    Li, C.5    Davis, J.M.6
  • 23
    • 60349086480 scopus 로고    scopus 로고
    • A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia
    • Leucht S, Komossa K, Rummel-Kluge C et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am. J. Psychiatry 166(2), 152-163 (2009).
    • (2009) Am. J. Psychiatry , vol.166 , Issue.2 , pp. 152-163
    • Leucht, S.1    Komossa, K.2    Rummel-Kluge, C.3
  • 24
    • 62849099049 scopus 로고    scopus 로고
    • How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials
    • Leucht S, Arbter D, Engel RR, Kissling W, Davis JM. How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Mol. Psychiatry 14(4), 429-447 (2009).
    • (2009) Mol. Psychiatry , vol.14 , Issue.4 , pp. 429-447
    • Leucht, S.1    Arbter, D.2    Engel, R.R.3    Kissling, W.4    Davis, J.M.5
  • 26
    • 0026772116 scopus 로고
    • Clinical and biologic response to clozapine in patients with schizophrenia. Crossover comparison with fluphenazine
    • Pickar D, Owen RR, Litman RE, Konicki E, Gutierrez R, Rapaport MH. Clinical and biologic response to clozapine in patients with schizophrenia. Crossover comparison with fluphenazine. Arch. Gen. Psychiatry 49(5), 345-353 (1992).
    • (1992) Arch. Gen. Psychiatry , vol.49 , Issue.5 , pp. 345-353
    • Pickar, D.1    Owen, R.R.2    Litman, R.E.3    Konicki, E.4    Gutierrez, R.5    Rapaport, M.H.6
  • 29
    • 0030825390 scopus 로고    scopus 로고
    • A double-blind comparative study of clozapine versus chlorpromazine on Chinese patients with treatment-refractory schizophrenia
    • Hong CJ, Chen JY, Chiu HJ, Sim CB. A double-blind comparative study of clozapine versus chlorpromazine on Chinese patients with treatment-refractory schizophrenia. Int. Clin. Psychopharmacol. 12(3), 123-130 (1997). (Pubitemid 27283319)
    • (1997) International Clinical Psychopharmacology , vol.12 , Issue.3 , pp. 123-130
    • Hong, C.J.1    Chen, J.Y.2    Chiu, H.J.3    Sim, C.B.4
  • 30
    • 0030756517 scopus 로고    scopus 로고
    • A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia
    • DOI 10.1056/NEJM199709183371202
    • Rosenheck R, Cramer J, Xu W et al. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. N. Engl. J. Med. 337(12), 809-815 (1997). (Pubitemid 27391630)
    • (1997) New England Journal of Medicine , vol.337 , Issue.12 , pp. 809-815
    • Rosenheck, R.1    Cramer, J.2    Xu, W.3    Thomas, J.4    Henderson, W.5    Frisman, L.6    Fye, C.7    Charney, D.8
  • 31
    • 0031746826 scopus 로고    scopus 로고
    • Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome
    • Buchanan RW, Breier A, Kirkpatrick B, Ball P, Carpenter WT Jr. Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome. Am. J. Psychiatry 155(6), 751-760 (1998). (Pubitemid 28252653)
    • (1998) American Journal of Psychiatry , vol.155 , Issue.6 , pp. 751-760
    • Buchanan, R.W.1    Breier, A.2    Kirkpatrick, B.3    Ball, P.4    Carpenter, W.T.5
  • 41
    • 0034761326 scopus 로고    scopus 로고
    • Risperidone versus haloperidol in the treatment of acute exacerbations of chronic inpatients with schizophrenia: A randomized double-blind study
    • Zhang XY, Zhou DF, Cao LY, Zhang PY, Wu GY, Shen YC. Risperidone versus haloperidol in the treatment of acute exacerbations of chronic inpatients with schizophrenia: a randomized double-blind study. Int. Clin Psychopharmacol. 16(6), 325-330 (2001).
    • (2001) Int. Clin Psychopharmacol. , vol.16 , Issue.6 , pp. 325-330
    • Zhang, X.Y.1    Zhou, D.F.2    Cao, L.Y.3    Zhang, P.Y.4    Wu, G.Y.5    Shen, Y.C.6
  • 45
    • 0033558072 scopus 로고    scopus 로고
    • Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia
    • DOI 10.1016/S0006-3223(98)00291-1, PII S0006322398002911
    • Breier A, Hamilton SH. Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia. Biol. Psychiatry 45(4), 403-411 (1999). (Pubitemid 29130436)
    • (1999) Biological Psychiatry , vol.45 , Issue.4 , pp. 403-411
    • Breier, A.1    Hamilton, S.H.2
  • 46
    • 0035060791 scopus 로고    scopus 로고
    • Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine
    • DOI 10.1016/S0006-3223(00)01026-X, PII S000632230001026X
    • Tollefson GD, Birkett MA, Kiesler GM, Wood AJ. Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine. Biol. Psychiatry 49(1), 52-63 (2001). (Pubitemid 32332954)
    • (2001) Biological Psychiatry , vol.49 , Issue.1 , pp. 52-63
    • Tollefson, G.D.1    Birkett, M.A.2    Kiesler, G.M.3    Wood, A.J.4
  • 47
    • 0344851930 scopus 로고    scopus 로고
    • The efficacy of high-dose olanzapine versus clozapine in treatment-resistant schizophrenia: A double-blind, crossover study [5]
    • Conley RR, Kelly DL, Richardson CM, Tamminga CA, Carpenter WT Jr. The efficacy of high-dose olanzapine versus clozapine in treatment-resistant schizophrenia: a double-blind crossover study. J. Clin. Psychopharmacol. 23(6), 668-671 (2003). (Pubitemid 37443202)
    • (2003) Journal of Clinical Psychopharmacology , vol.23 , Issue.6 , pp. 668-671
    • Conley, R.R.1    Kelly, D.L.2    Richardson, C.M.3    Tamminga, C.A.4    Carpenter Jr., W.T.5
  • 48
    • 0842327252 scopus 로고    scopus 로고
    • Adverse Effects and Laboratory Parameters of High-Dose Olanzapine vs. Clozapine in Treatment-Resistant Schizophrenia
    • DOI 10.1023/B:ACLI.0000008171.90644.f8
    • Kelly DL, Conley RR, Richardson CM, Tamminga CA, Carpenter WT Jr. Adverse effects and laboratory parameters of high-dose olanzapine vs. clozapine in treatment-resistant schizophrenia. Ann. Clin. Psychiatry 15(3-4), 181-186 (2003). (Pubitemid 38176337)
    • (2003) Annals of Clinical Psychiatry , vol.15 , Issue.3-4 , pp. 181-186
    • Kelly, D.L.1    Conley, R.R.2    Richardson, C.M.3    Tamminga, C.A.4    Carpenter Jr., W.T.5
  • 51
    • 33745726692 scopus 로고    scopus 로고
    • Childhood-onset schizophrenia: A double-blind, randomized clozapine-olanzapine comparison
    • Shaw P, Sporn A, Gogtay N et al. Childhood-onset schizophrenia: a double-blind, randomized clozapine-olanzapine comparison. Arch. Gen. Psychiatry 63(7), 721-730 (2006).
    • (2006) Arch. Gen. Psychiatry , vol.63 , Issue.7 , pp. 721-730
    • Shaw, P.1    Sporn, A.2    Gogtay, N.3
  • 53
    • 38949096818 scopus 로고    scopus 로고
    • Clozapine and "High-Dose" Olanzapine in Refractory Early-Onset Schizophrenia: A 12-Week Randomized and Double-Blind Comparison
    • DOI 10.1016/j.biopsych.2007.04.043, PII S0006322307004799
    • Kumra S, Kranzler H, Gerbino-Rosen G et al. Clozapine and "high-dose" olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-blind comparison. Biol. Psychiatry 63(5), 524-529 (2008). (Pubitemid 351220784)
    • (2008) Biological Psychiatry , vol.63 , Issue.5 , pp. 524-529
    • Kumra, S.1    Kranzler, H.2    Gerbino-Rosen, G.3    Kester, H.M.4    DeThomas, C.5    Kafantaris, V.6    Correll, C.U.7    Kane, J.M.8
  • 54
    • 0034075361 scopus 로고    scopus 로고
    • A comparison of the effects of quetiapine ('Seroquel') and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment
    • Emsley RA, Raniwalla J, Bailey PJ, Jones AM. A comparison of the effects of quetiapine ('seroquel') and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment. PRIZE Study Group. Int. Clin. Psychopharmacol. 15(3), 121-131 (2000). (Pubitemid 30326047)
    • (2000) International Clinical Psychopharmacology , vol.15 , Issue.3 , pp. 121-131
    • Emsley, R.A.1    Raniwalla, J.2    Bailey, P.J.3    Jones, A.M.4
  • 55
    • 31744435890 scopus 로고    scopus 로고
    • Efficacy and tolerability of ziprasidone in patients with treatment-resistant schizophrenia
    • DOI 10.1097/01.yic.0000182114.65134.81
    • Kane JM, Khanna S, Rajadhyaksha S, Giller E. Efficacy and tolerability of ziprasidone in patients with treatment-resistant schizophrenia. Int. Clin. Psychopharmacol. 21(1), 21-28 (2006). (Pubitemid 43175119)
    • (2006) International Clinical Psychopharmacology , vol.21 , Issue.1 , pp. 21-28
    • Kane, J.M.1    Khanna, S.2    Rajadhyaksha, S.3    Giller, E.4
  • 56
    • 67649842418 scopus 로고    scopus 로고
    • Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: The MOZART study
    • Sacchetti E, Galluzzo A, Valsecchi P, Romeo F, Gorini B, Warrington L. Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: the MOZART study. Schizophr. Res. 113(1), 112-121 (2009).
    • (2009) Schizophr. Res. , vol.113 , Issue.1 , pp. 112-121
    • Sacchetti, E.1    Galluzzo, A.2    Valsecchi, P.3    Romeo, F.4    Gorini, B.5    Warrington, L.6
  • 57
    • 33847656202 scopus 로고    scopus 로고
    • Aripiprazole for treatment-resistant schizophrenia: Results of a multicenter, randomized, double-blind, comparison study versus perphenazine
    • Kane JM, Meltzer HY, Carson WH Jr, McQuade RD, Marcus RN, Sanchez R. Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine. J. Clin. Psychiatry 68(2), 213-223 (2007). (Pubitemid 46362642)
    • (2007) Journal of Clinical Psychiatry , vol.68 , Issue.2 , pp. 213-223
    • Kane, J.M.1    Meltzer, H.Y.2    Carson Jr., W.H.3    McQuade, R.D.4    Marcus, R.N.5    Sanchez, R.6
  • 59
    • 68149160037 scopus 로고    scopus 로고
    • Oral antipsychotics for the treatment of schizophrenia: Heterogeneity in efficacy and tolerability should drive decision-making
    • Volavka J, Citrome L. Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making. Expert Opin. Pharmacother. 10(12), 1917-1928 (2009).
    • (2009) Expert Opin. Pharmacother. , vol.10 , Issue.12 , pp. 1917-1928
    • Volavka, J.1    Citrome, L.2
  • 60
    • 0037278766 scopus 로고    scopus 로고
    • Antipsychotic medication coprescribing in a large state hospital system
    • DOI 10.1002/pds.783
    • Jaffe AB, Levine J. Antipsychotic medication coprescribing in a large state hospital system. Pharmacoepidemiol. Drug Saf. 12(1), 41-48 (2003). (Pubitemid 36192948)
    • (2003) Pharmacoepidemiology and Drug Safety , vol.12 , Issue.1 , pp. 41-48
    • Jaffe, A.B.1    Levine, J.2
  • 61
    • 17144391387 scopus 로고    scopus 로고
    • Monotherapy versus polypharmacy for hospitalized psychiatric patients
    • Citrome L, Jaffe A, Levine J. Monotherapy versus polypharmacy for hospitalized psychiatric patients. Am. J. Psychiatry 162(3), 631 (2005).
    • (2005) Am. J. Psychiatry , vol.162 , Issue.3 , pp. 631
    • Citrome, L.1    Jaffe, A.2    Levine, J.3
  • 62
    • 0024443180 scopus 로고
    • Clozapine in China: A review and preview of US/PRC collaboration
    • Potter WZ, Ko GN, Zhang LD, Yan WW. Clozapine in China: a review and preview of US/PRC collaboration. Psychopharmacology (Berl.) 99(Suppl.), S87-S91 (1989). (Pubitemid 19244148)
    • (1989) Psychopharmacology , vol.99 , Issue.SUPPL.
    • Potter, W.Z.1    Ko, G.N.2    Zhang, L.D.3    Yan, W.4
  • 65
    • 13844311144 scopus 로고    scopus 로고
    • A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: Efficacy and safety
    • Anil Yaciolu AE, Kivircik Akdede BB, Turgut TI et al. A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. J. Clin. Psychiatry 66(1), 63-72 (2005).
    • (2005) J. Clin. Psychiatry , vol.66 , Issue.1 , pp. 63-72
    • Anil Yaciolu, A.E.1    Kivircik Akdede, B.B.2    Turgut, T.I.3
  • 68
    • 34147137079 scopus 로고    scopus 로고
    • Risperidone augmentation for schizophrenia partially responsive to clozapine: A double-blind, placebo-controlled trial
    • DOI 10.1016/j.schres.2006.12.030, PII S0920996407000321
    • Freudenreich O, Henderson DC, Walsh JP, Culhane MA, Goff DC. Risperidone augmentation for schizophrenia partially responsive to clozapine: a double-blind, placebo-controlled trial. Schizophr. Res. 92(1-3), 90-94 (2007). (Pubitemid 46561216)
    • (2007) Schizophrenia Research , vol.92 , Issue.1-3 , pp. 90-94
    • Freudenreich, O.1    Henderson, D.C.2    Walsh, J.P.3    Culhane, M.A.4    Goff, D.C.5
  • 69
    • 78651343292 scopus 로고    scopus 로고
    • Adjunctive risperidone for partially responsive people with schizophrenia treated with clozapine
    • Weiner E, Conley RR, Ball MP et al. Adjunctive risperidone for partially responsive people with schizophrenia treated with clozapine. Neuropsychopharmacology 35(11), 2274-2283 (2010).
    • (2010) Neuropsychopharmacology , vol.35 , Issue.11 , pp. 2274-2283
    • Weiner, E.1    Conley, R.R.2    Ball, M.P.3
  • 70
    • 33645215658 scopus 로고    scopus 로고
    • Amisulpride treatment of clozapine-induced hypersalivation in schizophrenia patients: A randomized, double-blind, placebo-controlled cross-over study
    • DOI 10.1097/01.yic.0000188216.92408.69, PII 0000485020060300000005
    • Kreinin A, Novitski D, Weizman A. Amisulpride treatment of clozapine-induced hypersalivation in schizophrenia patients: a randomized, double-blind, placebo controlled cross-over study. Int. Clin. Psychopharmacol. 21(2), 99-103 (2006). (Pubitemid 43740317)
    • (2006) International Clinical Psychopharmacology , vol.21 , Issue.2 , pp. 99-103
    • Kreinin, A.1    Novitski, D.2    Weizman, A.3
  • 71
    • 38849155770 scopus 로고    scopus 로고
    • Amisulpride augmentation in patients with schizophrenia partially responsive or unresponsive to clozapine. A randomized, double-blind, placebo-controlled trial
    • DOI 10.1055/s-2007-993209
    • Assion HJ, Reinbold H, Lemanski S, Basilowski M, Juckel G. Amisulpride augmentation in patients with schizophrenia partially responsive or unresponsive to clozapine. A randomized, double-blind, placebo-controlled trial. Pharmacopsychiatry 41(1), 24-28 (2008). (Pubitemid 351195889)
    • (2008) Pharmacopsychiatry , vol.41 , Issue.1 , pp. 24-28
    • Assion, H.-J.1    Reinbold, H.2    Lemanski, S.3    Basilowski, M.4    Juckel, G.5
  • 72
    • 34247846196 scopus 로고    scopus 로고
    • Comparison of clozapine-amisulpride and clozapine-quetiapine combinations for patients with schizophrenia who are partially responsive to clozapine: A single-blind randomized study
    • Genç Y, Taner E, Candansayar S. Comparison of clozapine- amisulpride and clozapine-quetiapine combinations for patients with schizophrenia who are partially responsive to clozapine: a single-blind randomized study. Adv. Ther. 24(1), 1-13 (2007). (Pubitemid 46700860)
    • (2007) Advances in Therapy , vol.24 , Issue.1 , pp. 1-13
    • Genc, Y.1    Taner, E.2    Candansayar, S.3
  • 73
    • 45249113944 scopus 로고    scopus 로고
    • Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: An 8-week, randomized, double-blind, placebo-controlled trial
    • Chang JS, Ahn YM, Park HJ et al. Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial. J. Clin. Psychiatry 69(5), 720-731 (2008). (Pubitemid 351838681)
    • (2008) Journal of Clinical Psychiatry , vol.69 , Issue.5 , pp. 720-731
    • Chang, J.S.1    Ahn, Y.M.2    Park, H.J.3    Lee, K.Y.4    Kim, S.H.5    Kang, U.G.6    Kim, Y.S.7
  • 74
    • 77957230409 scopus 로고    scopus 로고
    • Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: A randomized, double-blind, placebo-controlled trial
    • Fleischhacker WW, Heikkinen ME, Olié JP et al. Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial. Int. J. Neuropsychopharmacol. 13(8), 1115-1125 (2010).
    • (2010) Int. J. Neuropsychopharmacol. , vol.13 , Issue.8 , pp. 1115-1125
    • Fleischhacker, W.W.1    Heikkinen, M.E.2    Olié, J.P.3
  • 75
    • 79952360373 scopus 로고    scopus 로고
    • Effect of aripiprazole augmentation of clozapine in schizophrenia: A double-blind, placebo-controlled study
    • Muscatello MR, Bruno A, Pandolfo G et al. Effect of aripiprazole augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study. Schizophr. Res. 127(1-3), 93-99 (2011).
    • (2011) Schizophr. Res. , vol.127 , Issue.1-3 , pp. 93-99
    • Muscatello, M.R.1    Bruno, A.2    Pandolfo, G.3
  • 76
    • 65349177685 scopus 로고    scopus 로고
    • Efficacy and tolerability of ziprasidone versus risperidone as augmentation in patients partially responsive to clozapine: A randomised controlled clinical trial
    • Zink M, Kuwilsky A, Krumm B, Dressing H. Efficacy and tolerability of ziprasidone versus risperidone as augmentation in patients partially responsive to clozapine: a randomised controlled clinical trial. J. Psychopharmacol. 23(3), 305-314 (2009).
    • (2009) J. Psychopharmacol. , vol.23 , Issue.3 , pp. 305-314
    • Zink, M.1    Kuwilsky, A.2    Krumm, B.3    Dressing, H.4
  • 77
    • 72849140996 scopus 로고    scopus 로고
    • A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy
    • Kane JM, Correll CU, Goff DC et al. A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. J. Clin. Psychiatry 70(10), 1348-1357 (2009).
    • (2009) J. Clin. Psychiatry , vol.70 , Issue.10 , pp. 1348-1357
    • Kane, J.M.1    Correll, C.U.2    Goff, D.C.3
  • 78
    • 67649313808 scopus 로고    scopus 로고
    • Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients
    • Henderson DC, Fan X, Copeland PM et al. Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients. J. Clin. Psychopharmacol. 29(2), 165-169 (2009).
    • (2009) J. Clin. Psychopharmacol. , vol.29 , Issue.2 , pp. 165-169
    • Henderson, D.C.1    Fan, X.2    Copeland, P.M.3
  • 79
    • 70349229549 scopus 로고    scopus 로고
    • Augmentation of olanzapine by fluphenazine decanoate in poorly responsive schizophrenia
    • Shafti SS. Augmentation of olanzapine by fluphenazine decanoate in poorly responsive schizophrenia. Clin. Schizophr. Relat. Psychoses 3(2), 97-102 (2009).
    • (2009) Clin. Schizophr. Relat. Psychoses , vol.3 , Issue.2 , pp. 97-102
    • Shafti, S.S.1
  • 80
    • 1642534546 scopus 로고    scopus 로고
    • Sulpiride augmentation of olanzapine in the management of treatment-resistant chronic schizophrenia: Evidence for improvement of mood symptomatology
    • DOI 10.1097/00004850-200401000-00004
    • Kotler M, Strous RD, Reznik I, Shwartz S, Weizman A, Spivak B. Sulpiride augmentation of olanzapine in the management of treatment-resistant chronic schizophrenia: evidence for improvement of mood symptomatology. Int. Clin. Psychopharmacol. 19(1), 23-26 (2004). (Pubitemid 38114620)
    • (2004) International Clinical Psychopharmacology , vol.19 , Issue.1 , pp. 23-26
    • Kotler, M.1    Strous, R.D.2    Reznik, I.3    Shwartz, S.4    Weizman, A.5    Spivak, B.6
  • 81
    • 0033017285 scopus 로고    scopus 로고
    • Comparison of risperidone and mosapramine addition to neuroleptic treatment in chronic schizophrenia
    • Takahashi N, Terao T, Oga T, Okada M. Comparison of risperidone and mosapramine addition to neuroleptic treatment in chronic schizophrenia. Neuropsychobiology 39(2), 81-85 (1999). (Pubitemid 29118955)
    • (1999) Neuropsychobiology , vol.39 , Issue.2 , pp. 81-85
    • Takahashi, N.1    Terao, T.2    Oga, T.3    Okada, M.4
  • 82
    • 70049104227 scopus 로고    scopus 로고
    • Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia
    • Cipriani A, Boso M, Barbui C. Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia. Cochrane Database Syst. Rev. 8(3), CD006324 (2009).
    • (2009) Cochrane Database Syst. Rev. , vol.8 , Issue.3
    • Cipriani, A.1    Boso, M.2    Barbui, C.3
  • 83
    • 0034100648 scopus 로고    scopus 로고
    • Changes in use of valproate and other mood stabilizers for patients with schizophrenia from 1994 to 1998
    • DOI 10.1176/appi.ps.51.5.634
    • Citrome L, Levine J, Allingham B. Changes in use of valproate and other mood stabilizers for patients with schizophrenia from 1994 to 1998. Psychiatr. Serv. 51(5), 634-638 (2000). (Pubitemid 30256639)
    • (2000) Psychiatric Services , vol.51 , Issue.5 , pp. 634-638
    • Citrome, L.1    Levine, J.2    Allingham, B.3
  • 84
    • 0036787358 scopus 로고    scopus 로고
    • Use of mood stabilizers among patients with schizophrenia 1994-2001
    • Citrome L, Jaffe A, Levine J, Allingham B. Use of mood stabilizers among patients with schizophrenia, 1994-2001. Psychiatr. Serv. 53(10), 1212 (2002).
    • (2002) Psychiatr. Serv. , vol.53 , Issue.10 , pp. 1212
    • Citrome, L.1    Jaffe, A.2    Levine, J.3    Allingham, B.4
  • 85
    • 58149230875 scopus 로고    scopus 로고
    • Adjunctive lithium and anticonvulsants for the treatment of schizophrenia: What is the evidence?
    • Citrome L. Adjunctive lithium and anticonvulsants for the treatment of schizophrenia: what is the evidence? Expert Rev. Neurother. 9(1), 55-71 (2009).
    • (2009) Expert Rev. Neurother. , vol.9 , Issue.1 , pp. 55-71
    • Citrome, L.1
  • 86
    • 62649086513 scopus 로고    scopus 로고
    • The efficacy of lamotrigine in clozapine-resistant schizophrenia: A systematic review and meta-analysis
    • Tiihonen J, Wahlbeck K, Kiviniemi V. The efficacy of lamotrigine in clozapine-resistant schizophrenia: a systematic review and meta-analysis. Schizophr. Res. 109(1-3), 10-14 (2009).
    • (2009) Schizophr. Res. , vol.109 , Issue.1-3 , pp. 10-14
    • Tiihonen, J.1    Wahlbeck, K.2    Kiviniemi, V.3
  • 87
    • 54049091644 scopus 로고    scopus 로고
    • Schizophrenia, obesity, and antipsychotic medications: What can we do?
    • Citrome L, Vreeland B. Schizophrenia, obesity, and antipsychotic medications: what can we do? Postgrad. Med. 120(2), 18-33 (2008).
    • (2008) Postgrad. Med. , vol.120 , Issue.2 , pp. 18-33
    • Citrome, L.1    Vreeland, B.2
  • 89
    • 20444405296 scopus 로고    scopus 로고
    • Celecoxib augmentation of continuously Ill patients with schizophrenia
    • DOI 10.1016/j.biopsych.2005.02.024, PII S0006322305001897
    • Rapaport MH, Delrahim KK, Bresee CJ, Maddux RE, Ahmadpour O, Dolnak D. Celecoxib augmentation of continuously ill patients with schizophrenia. Biol. Psychiatry 57(12), 1594-1596 (2005). (Pubitemid 40805391)
    • (2005) Biological Psychiatry , vol.57 , Issue.12 , pp. 1594-1596
    • Rapaport, M.H.1    Delrahim, K.K.2    Bresee, C.J.3    Maddux, R.E.4    Ahmadpour, O.5    Dolnak, D.6
  • 90
    • 33846620518 scopus 로고    scopus 로고
    • Celecoxib as adjunctive therapy in schizophrenia: A double-blind, randomized and placebo-controlled trial
    • DOI 10.1016/j.schres.2006.11.016, PII S0920996406004956
    • Akhondzadeh S, Tabatabaee M, Amini H, Ahmadi Abhari SA, Abbasi SH, Behnam B. Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial. Schizophr. Res. 90(1-3), 179-185 (2007). (Pubitemid 46177578)
    • (2007) Schizophrenia Research , vol.90 , Issue.1-3 , pp. 179-185
    • Akhondzadeh, S.1    Tabatabaee, M.2    Amini, H.3    Ahmadi Abhari, S.A.4    Abbasi, S.H.5    Behnam, B.6
  • 91
    • 77955050321 scopus 로고    scopus 로고
    • Celecoxib treatment in an early stage of schizophrenia: Results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment
    • Müller N, Krause D, Dehning S et al. Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment. Schizophr. Res. 121(1-3), 118-124 (2010).
    • (2010) Schizophr. Res. , vol.121 , Issue.1-3 , pp. 118-124
    • Müller, N.1    Krause, D.2    Dehning, S.3
  • 92
    • 77952641170 scopus 로고    scopus 로고
    • Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: Results from a randomized, double-blind, placebo-controlled trial
    • Laan W, Grobbee DE, Selten JP et al. Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial. J. Clin. Psychiatry 71(5), 520-527 (2010).
    • (2010) J. Clin. Psychiatry , vol.71 , Issue.5 , pp. 520-527
    • Laan, W.1    Grobbee, D.E.2    Selten, J.P.3
  • 93
    • 0023250446 scopus 로고
    • Adjunctive imipramine in the treatment of postpsychotic depression: A controlled trial
    • Siris SG, Morgan V, Fagerstrom R, Rifkin A, Cooper TB. Adjunctive imipramine in the treatment of postpsychotic depression. A controlled trial. Arch. Gen. Psychiatry 44(6), 533-539 (1987). (Pubitemid 17082094)
    • (1987) Archives of General Psychiatry , vol.44 , Issue.6 , pp. 533-539
    • Siris, S.G.1    Morgan, V.2    Fagerstrom, R.3
  • 98
    • 0027954581 scopus 로고
    • Maintenance imipramine therapy for secondary depression in schizophrenia: A controlled trial
    • Siris SG, Bermanzohn PC, Mason SE, Shuwall MA. Maintenance imipramine therapy for secondary depression in schizophrenia. A controlled trial. Arch. Gen. Psychiatry 51(2), 109-115 (1994). (Pubitemid 24054312)
    • (1994) Archives of General Psychiatry , vol.51 , Issue.2 , pp. 109-115
    • Siris, S.G.1    Bermanzohn, P.C.2    Mason, S.E.3    Shuwall, M.A.4
  • 99
    • 0028937511 scopus 로고
    • Citalopram, a selective serotonin reuptake inhibitor, in the treatment of aggression in schizophrenia
    • Vartiainen H, Tiihonen J, Putkonen A et al. Citalopram, a selective serotonin reuptake inhibitor, in the treatment of aggression in schizophrenia. Acta Psychiatr. Scand. 91(5), 348-351 (1995).
    • (1995) Acta Psychiatr. Scand. , vol.91 , Issue.5 , pp. 348-351
    • Vartiainen, H.1    Tiihonen, J.2    Putkonen, A.3
  • 103
    • 18844394326 scopus 로고    scopus 로고
    • The effect of citalopram adjunctive treatment added to atypical antipsychotic medications for cognitive performance in patients with schizophrenia
    • DOI 10.1097/01.jcp.0000161499.58266.51
    • Friedman JI, Ocampo R, Elbaz Z et al. The effect of citalopram adjunctive treatment added to atypical antipsychotic medications for cognitive performance in patients with schizophrenia. J. Clin. Psychopharmacol. 25(3), 237-242 (2005). (Pubitemid 40685787)
    • (2005) Journal of Clinical Psychopharmacology , vol.25 , Issue.3 , pp. 237-242
    • Friedman, J.I.1    Ocampo, R.2    Elbaz, Z.3    Parrella, M.4    White, L.5    Bowler, S.6    Davis, K.L.7    Harvey, P.D.8
  • 104
    • 66349133105 scopus 로고    scopus 로고
    • Citalopram augmentation for subsyndromal symptoms of depression in middle-aged and older outpatients with schizophrenia and schizoaffective disorder: A randomized controlled trial
    • Zisook S, Kasckow JW, Golshan S et al. Citalopram augmentation for subsyndromal symptoms of depression in middle-aged and older outpatients with schizophrenia and schizoaffective disorder: a randomized controlled trial. J. Clin. Psychiatry 70(4), 562-571 (2009).
    • (2009) J. Clin. Psychiatry , vol.70 , Issue.4 , pp. 562-571
    • Zisook, S.1    Kasckow, J.W.2    Golshan, S.3
  • 105
    • 77955294108 scopus 로고    scopus 로고
    • Augmentation with citalopram for suicidal ideation in middle-aged and older outpatients with schizophrenia and schizoaffective disorder who have subthreshold depressive symptoms: A randomized controlled trial
    • Zisook S, Kasckow JW, Lanouette NM et al. Augmentation with citalopram for suicidal ideation in middle-aged and older outpatients with schizophrenia and schizoaffective disorder who have subthreshold depressive symptoms: a randomized controlled trial. J. Clin. Psychiatry 71(7), 915-922 (2010).
    • (2010) J. Clin. Psychiatry , vol.71 , Issue.7 , pp. 915-922
    • Zisook, S.1    Kasckow, J.W.2    Lanouette, N.M.3
  • 106
    • 75749098133 scopus 로고    scopus 로고
    • Treatment of subsyndromal depressive symptoms in middle-aged and older adults with schizophrenia: Effect on functioning
    • Kasckow J, Lanouette N, Patterson T et al. Treatment of subsyndromal depressive symptoms in middle-aged and older adults with schizophrenia: effect on functioning. Int. J. Geriatr. Psychiatry 25(2), 183-190 (2010).
    • (2010) Int. J. Geriatr. Psychiatry , vol.25 , Issue.2 , pp. 183-190
    • Kasckow, J.1    Lanouette, N.2    Patterson, T.3
  • 107
    • 77955429638 scopus 로고    scopus 로고
    • Escitalopram in the treatment of negative symptoms in patients with chronic schizophrenia: A randomized double-blind placebo-controlled trial
    • Iancu I, Tschernihovsky E, Bodner E, Piconne AS, Lowengrub K. Escitalopram in the treatment of negative symptoms in patients with chronic schizophrenia: a randomized double-blind placebo-controlled trial. Psychiatry Res. 179(1), 19-23 (2010).
    • (2010) Psychiatry Res. , vol.179 , Issue.1 , pp. 19-23
    • Iancu, I.1    Tschernihovsky, E.2    Bodner, E.3    Piconne, A.S.4    Lowengrub, K.5
  • 110
    • 0026686088 scopus 로고
    • Fluvoxamine improves negative symptoms in treated chronic schizophrenia: An add-on double-blind, placebo-controlled study
    • Silver H, Nassar A. Fluvoxamine improves negative symptoms in treated chronic schizophrenia: an add-on double-blind, placebo-controlled study. Biol. Psychiatry 31(7), 698-704 (1992).
    • (1992) Biol. Psychiatry , vol.31 , Issue.7 , pp. 698-704
    • Silver, H.1    Nassar, A.2
  • 111
    • 0033845691 scopus 로고    scopus 로고
    • Fluvoxamine augmentation of antipsychotics improves negative symptoms in psychotic chronic schizophrenic patients: A placebo-controlled study
    • Silver H, Barash I, Aharon N, Kaplan A, Poyurovsky M. Fluvoxamine augmentation of antipsychotics improves negative symptoms in psychotic chronic schizophrenic patients: a placebo-controlled study. Int. Clin. Psychopharmacol. 15(5), 257-261 (2000). (Pubitemid 30660960)
    • (2000) International Clinical Psychopharmacology , vol.15 , Issue.5 , pp. 257-261
    • Silver, H.1    Barash, I.2    Aharon, N.3    Kaplan, A.4    Poyurovsky, M.5
  • 112
    • 4243182676 scopus 로고    scopus 로고
    • Olanzapine plus fluvoxamine and olanzapine alone for the treatment of an acute exacerbation of schizophrenia
    • DOI 10.1111/j.1440-1819.2004.01269.x
    • Chaichan W. Olanzapine plus fluvoxamine and olanzapine alone for the treatment of an acute exacerbation of schizophrenia. Psychiatry Clin. Neurosci. 58(4), 364-368 (2004). (Pubitemid 39108537)
    • (2004) Psychiatry and Clinical Neurosciences , vol.58 , Issue.4 , pp. 364-368
    • Chaichan, W.1
  • 113
    • 0035116237 scopus 로고    scopus 로고
    • Efficacy of mirtazapine add on therapy to haloperidol in the treatment of the negative symptoms of schizophrenia: A double-blind randomized placebo-controlled study
    • Berk M, Ichim C, Brook S. Efficacy of mirtazapine add on therapy to haloperidol in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study. Int. Clin. Psychopharmacol. 16(2), 87-92 (2001). (Pubitemid 32171833)
    • (2001) International Clinical Psychopharmacology , vol.16 , Issue.2 , pp. 87-92
    • Berk, M.1    Ichim, C.2    Brook, S.3
  • 115
    • 67649723855 scopus 로고    scopus 로고
    • Mirtazapine add-on therapy in the treatment of schizophrenia with atypical antipsychotics: A double-blind, randomised, placebo-controlled clinical trial
    • Berk M, Gama CS, Sundram S et al. Mirtazapine add-on therapy in the treatment of schizophrenia with atypical antipsychotics: a double-blind, randomised, placebo-controlled clinical trial. Hum. Psychopharmacol. 24(3), 233-238 (2009).
    • (2009) Hum. Psychopharmacol. , vol.24 , Issue.3 , pp. 233-238
    • Berk, M.1    Gama, C.S.2    Sundram, S.3
  • 116
    • 60249102800 scopus 로고    scopus 로고
    • Add-on mirtazapine enhances antipsychotic effect of first generation antipsychotics in schizophrenia: A double-blind, randomized, placebo-controlled trial
    • Joffe G, Terevnikov V, Joffe M, Stenberg JH, Burkin M, Tiihonen J. Add-on mirtazapine enhances antipsychotic effect of first generation antipsychotics in schizophrenia: a double-blind, randomized, placebo-controlled trial. Schizophr. Res. 108(1-3), 245-251 (2009).
    • (2009) Schizophr. Res. , vol.108 , Issue.1-3 , pp. 245-251
    • Joffe, G.1    Terevnikov, V.2    Joffe, M.3    Stenberg, J.H.4    Burkin, M.5    Tiihonen, J.6
  • 117
    • 77953540588 scopus 로고    scopus 로고
    • Effects of add-on mirtazapine on neurocognition in schizophrenia: A double-blind, randomized, placebo-controlled study
    • Stenberg JH, Terevnikov V, Joffe M et al. Effects of add-on mirtazapine on neurocognition in schizophrenia: a double-blind, randomized, placebo-controlled study. Int. J. Neuropsychopharmacol. 13(4), 433-441 (2010).
    • (2010) Int. J. Neuropsychopharmacol. , vol.13 , Issue.4 , pp. 433-441
    • Stenberg, J.H.1    Terevnikov, V.2    Joffe, M.3
  • 118
    • 74449083580 scopus 로고    scopus 로고
    • The effect of mirtazapine add-on therapy to risperidone in the treatment of schizophrenia: A double-blind randomized placebo-controlled trial
    • Abbasi SH, Behpournia H, Ghoreshi A et al. The effect of mirtazapine add-on therapy to risperidone in the treatment of schizophrenia: a double-blind randomized placebo-controlled trial. Schizophr. Res. 116(2-3), 101-106 (2010).
    • (2010) Schizophr. Res. , vol.116 , Issue.2-3 , pp. 101-106
    • Abbasi, S.H.1    Behpournia, H.2    Ghoreshi, A.3
  • 119
    • 78650943515 scopus 로고    scopus 로고
    • Mirtazapine augmentation enhances cognitive and reduces negative symptoms in schizophrenia patients treated with risperidone: A randomized controlled trial
    • Cho SJ, Yook K, Kim B et al. Mirtazapine augmentation enhances cognitive and reduces negative symptoms in schizophrenia patients treated with risperidone: a randomized controlled trial. Prog. Neuropsychopharmacol. Biol. Psychiatry 35(1), 208-211 (2011).
    • (2011) Prog. Neuropsychopharmacol. Biol. Psychiatry , vol.35 , Issue.1 , pp. 208-211
    • Cho, S.J.1    Yook, K.2    Kim, B.3
  • 121
    • 0344406216 scopus 로고    scopus 로고
    • Effect of the 5-HT2 antagonist mianserin on cognitive dysfunction in chronic schizophrenia patients: An add-on, double-blind placebo-controlled study
    • DOI 10.1016/S0924-977X(02)00155-4
    • Poyurovsky M, Koren D, Gonopolsky I et al. Effect of the 5-HT2 antagonist mianserin on cognitive dysfunction in chronic schizophrenia patients: an add-on, double-blind placebo-controlled study. Eur. Neuropsychopharmacol. 13(2), 123-128 (2003). (Pubitemid 36313287)
    • (2003) European Neuropsychopharmacology , vol.13 , Issue.2 , pp. 123-128
    • Poyurovsky, M.1    Koren, D.2    Gonopolsky, I.3    Schneidman, M.4    Fuchs, C.5    Weizman, A.6    Weizman, R.7
  • 122
    • 12144261224 scopus 로고    scopus 로고
    • Negative symptoms of schizophrenia are improved by the addition of paroxetine to neuroleptics: A double-blind placebo-controlled study
    • DOI 10.1097/00004850-200501000-00006
    • Jockers-Scherübl MC, Bauer A, Godemann F, Reischies FM, Selig F, Schlattmann P. Negative symptoms of schizophrenia are improved by the addition of paroxetine to neuroleptics: a double-blind placebo-controlled study. Int. Clin. Psychopharmacol. 20(1), 27-31 (2005). (Pubitemid 40105546)
    • (2005) International Clinical Psychopharmacology , vol.20 , Issue.1 , pp. 27-31
    • Jockers-Scherubl, M.C.1    Bauer, A.2    Godemann, F.3    Reischies, F.M.4    Selig, F.5    Schlattmann, P.6
  • 123
    • 0034830758 scopus 로고    scopus 로고
    • Reboxetine add on therapy to haloperidol in the treatment of schizophrenia: A preliminary double-blind randomized placebo-controlled study
    • Schutz G, Berk M. Reboxetine add on therapy to haloperidol in the treatment of schizophrenia: a preliminary double-blind randomized placebo-controlled study. Int. Clin. Psychopharmacol. 16(5), 275-278 (2001). (Pubitemid 32822446)
    • (2001) International Clinical Psychopharmacology , vol.16 , Issue.5 , pp. 275-278
    • Schutz, G.1    Berk, M.2
  • 124
    • 56449125612 scopus 로고    scopus 로고
    • Effect of ritanserin, a 5HT2A/2C antagonist, on negative symptoms of schizophrenia: A double-blind randomized placebo-controlled study
    • Akhondzadeh S, Malek-Hosseini M, Ghoreishi A, Raznahan M, Rezazadeh SA. Effect of ritanserin, a 5HT2A/2C antagonist, on negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study. Prog. Neuropsychopharmacol. Biol. Psychiatry 32(8), 1879-1883 (2008).
    • (2008) Prog. Neuropsychopharmacol. Biol. Psychiatry , vol.32 , Issue.8 , pp. 1879-1883
    • Akhondzadeh, S.1    Malek-Hosseini, M.2    Ghoreishi, A.3    Raznahan, M.4    Rezazadeh, S.A.5
  • 125
    • 13444271621 scopus 로고    scopus 로고
    • Double-blind, placebo-controlled, multicenter trial of selegiline augmentation of antipsychotic medication to treat negative symptoms in outpatients with schizophrenia
    • DOI 10.1176/appi.ajp.162.2.388
    • Bodkin JA, Siris SG, Bermanzohn PC, Hennen J, Cole JO. Double-blind, placebo-controlled, multicenter trial of selegiline augmentation of antipsychotic medication to treat negative symptoms in outpatients with schizophrenia. Am. J. Psychiatry 162(2), 388-390 (2005). (Pubitemid 40216224)
    • (2005) American Journal of Psychiatry , vol.162 , Issue.2 , pp. 388-390
    • Bodkin, J.A.1    Siris, S.G.2    Bermanzohn, P.C.3    Hennen, J.4    Cole, J.O.5
  • 127
    • 0008762402 scopus 로고    scopus 로고
    • A double-blind study of adjunctive sertraline in haloperidol-stabilized patients with chronic schizophrenia
    • DOI 10.1097/00004714-199810000-00008
    • Lee MS, Kim YK, Lee SK, Suh KY. A double-blind study of adjunctive sertraline in haloperidol-stabilized patients with chronic schizophrenia. J. Clin. Psychopharmacol. 18(5), 399-403 (1998). (Pubitemid 28462630)
    • (1998) Journal of Clinical Psychopharmacology , vol.18 , Issue.5 , pp. 399-403
    • Lee, M.S.1    Kim, Y.K.2    Lee, S.K.3    Suh, K.Y.4
  • 130
    • 11844302940 scopus 로고    scopus 로고
    • Effects of adjunctive mifepristone (RU-486) administration on neurocognitive function and symptoms in schizophrenia
    • DOI 10.1016/j.biopsych.2004.10.017, PII S0006322304010972
    • Gallagher P, Watson S, Smith MS, Ferrier IN, Young AH. Effects of adjunctive mifepristone (RU-486) administration on neurocognitive function and symptoms in schizophrenia. Biol. Psychiatry 57(2), 155-161 (2005). (Pubitemid 40094715)
    • (2005) Biological Psychiatry , vol.57 , Issue.2 , pp. 155-161
    • Gallagher, P.1    Watson, S.2    Smith, M.S.3    Ferrier, I.N.4    Young, A.H.5
  • 133
    • 38349142770 scopus 로고    scopus 로고
    • A pilot study of adjunctive atomoxetine treatment to second-generation antipsychotics for cognitive impairment in schizophrenia
    • Friedman JI, Carpenter D, Lu J et al. A pilot study of adjunctive atomoxetine treatment to second-generation antipsychotics for cognitive impairment in schizophrenia. J. Clin. Psychopharmacol. 28(1), 59-63 (2008).
    • (2008) J. Clin. Psychopharmacol. , vol.28 , Issue.1 , pp. 59-63
    • Friedman, J.I.1    Carpenter, D.2    Lu, J.3
  • 134
    • 66349085040 scopus 로고    scopus 로고
    • A randomized double-blind trial of atomoxetine for cognitive impairments in 32 people with schizophrenia
    • Kelly DL, Buchanan RW, Boggs DL et al. A randomized double-blind trial of atomoxetine for cognitive impairments in 32 people with schizophrenia. J. Clin. Psychiatry 70(4), 518-525 (2009).
    • (2009) J. Clin. Psychiatry , vol.70 , Issue.4 , pp. 518-525
    • Kelly, D.L.1    Buchanan, R.W.2    Boggs, D.L.3
  • 137
    • 0036501411 scopus 로고    scopus 로고
    • A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia
    • DOI 10.1016/S0006-3223(01)01342-7, PII S0006322301013427
    • Friedman JI, Adler DN, Howanitz E et al. A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia. Biol. Psychiatry 51(5), 349-357 (2002). (Pubitemid 34251171)
    • (2002) Biological Psychiatry , vol.51 , Issue.5 , pp. 349-357
    • Friedman, J.I.1    Adler, D.N.2    Howanitz, E.3    Harvey, P.D.4    Brenner, G.5    Temporini, H.6    White, L.7    Parrella, M.8
  • 139
    • 17544402307 scopus 로고    scopus 로고
    • A double-blind, placebo controlled, cross-over trial of adjunctive donepezil for cognitive impairment in schizophrenia
    • DOI 10.1017/S1461145703004024
    • Tual O, Yazici KM, Anil Yaciolu AE, Göü A. A double-blind, placebo controlled, cross-over trial of adjunctive donepezil for cognitive impairment in schizophrenia. Int. J. Neuropsychopharmacol. 7(2), 117-123 (2004). (Pubitemid 38823278)
    • (2004) International Journal of Neuropsychopharmacology , vol.7 , Issue.2 , pp. 117-123
    • Tugal, O.1    Yazici, K.M.2    Yagcioglu, A.E.A.3    Gogus, A.4
  • 142
    • 33746423014 scopus 로고    scopus 로고
    • Donepezil for negative signs in elderly patients with schizophrenia: An add-on, double-blind, crossover, placebo-controlled study
    • DOI 10.1017/S1041610205003017, PII S1041610205003017
    • Mazeh D, Zemishlani H, Barak Y, Mirecki I, Paleacu D. Donepezil for negative signs in elderly patients with schizophrenia: an add-on, double-blind, crossover, placebo-controlled study. Int. Psychogeriatr. 18(3), 429-436 (2006). (Pubitemid 44128317)
    • (2006) International Psychogeriatrics , vol.18 , Issue.3 , pp. 429-436
    • Mazeh, D.1    Zemishlani, H.2    Barak, Y.3    Mirecki, I.4    Paleacu, D.5
  • 143
    • 33846815311 scopus 로고    scopus 로고
    • Effects of donepezil adjunctive treatment to ziprasidone on cognitive deficits in schizophrenia: A double-blind, placebo-controlled study
    • DOI 10.1097/01.WNF.0000240940.67241.F6, PII 0000282620070100000002
    • Fagerlund B, Søholm B, Fink-Jensen A, Lublin H, Glenthøj BY. Effects of donepezil adjunctive treatment to ziprasidone on cognitive deficits in schizophrenia: a double-blind, placebo-controlled study. Clin. Neuropharmacol. 30(1), 3-12 (2007). (Pubitemid 46204312)
    • (2007) Clinical Neuropharmacology , vol.30 , Issue.1 , pp. 3-12
    • Fagerlund, B.1    Soholm, B.2    Fink-Jensen, A.3    Lublin, H.4    Glenthoj, B.Y.5
  • 144
    • 34447546649 scopus 로고    scopus 로고
    • A 12-week, double-blind, placebo-controlled trial of donepezil as an adjunct to haloperidol for treating cognitive impairments in patients with chronic schizophrenia
    • Lee BJ, Lee JG, Kim YH. A 12-week, double-blind, placebo-controlled trial of donepezil as an adjunct to haloperidol for treating cognitive impairments in patients with chronic schizophrenia. J. Psychopharmacol. 21(4), 421-427 (2007).
    • (2007) J. Psychopharmacol. , vol.21 , Issue.4 , pp. 421-427
    • Lee, B.J.1    Lee, J.G.2    Kim, Y.H.3
  • 145
    • 34249317238 scopus 로고    scopus 로고
    • Double-blind donepezil-placebo crossover augmentation study of atypical antipsychotics in chronic, stable schizophrenia: A pilot study
    • DOI 10.1016/j.schres.2007.01.001, PII S0920996407000503
    • Risch SC, Horner MD, McGurk SR et al. Double-blind donepezil-placebo crossover augmentation study of atypical antipsychotics in chronic, stable schizophrenia: a pilot study. Schizophr. Res. 93(1-3), 131-135 (2007). (Pubitemid 46817923)
    • (2007) Schizophrenia Research , vol.93 , Issue.1-3 , pp. 131-135
    • Risch, S.C.1    Horner, M.D.2    McGurk, S.R.3    Palecko, S.4    Markowitz, J.S.5    Nahas, Z.6    DeVane, C.L.7
  • 146
    • 56549087519 scopus 로고    scopus 로고
    • A 12-week, double-blind, placebo-controlled trial of donepezil adjunctive treatment to risperidone in chronic and stable schizophrenia
    • Akhondzadeh S, Gerami M, Noroozian M et al. A 12-week, double-blind, placebo-controlled trial of donepezil adjunctive treatment to risperidone in chronic and stable schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 32(8), 1810-1815 (2008).
    • (2008) Prog. Neuropsychopharmacol. Biol. Psychiatry , vol.32 , Issue.8 , pp. 1810-1815
    • Akhondzadeh, S.1    Gerami, M.2    Noroozian, M.3
  • 147
    • 42049123448 scopus 로고    scopus 로고
    • Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: Significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial
    • DOI 10.1038/sj.npp.1301499, PII 1301499
    • Keefe RSE, Malhotra AK, Meltzer HY et al. Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology 33(6), 1217-1228 (2008). (Pubitemid 351521707)
    • (2008) Neuropsychopharmacology , vol.33 , Issue.6 , pp. 1217-1228
    • Keefe, R.S.E.1    Malhotra, A.K.2    Meltzer, H.Y.3    Kane, J.M.4    Buchanan, R.W.5    Murthy, A.6    Sovel, M.7    Li, C.8    Goldman, R.9
  • 148
    • 33748751285 scopus 로고    scopus 로고
    • Galantamine improves cognition in schizophrenic patients stabilized on risperidone
    • DOI 10.1016/j.biopsych.2006.04.006, PII S0006322306004689
    • Schubert MH, Young KA, Hicks PB. Galantamine improves cognition in schizophrenic patients stabilized on risperidone. Biol. Psychiatry 60(6), 530-533 (2006). (Pubitemid 44402376)
    • (2006) Biological Psychiatry , vol.60 , Issue.6 , pp. 530-533
    • Schubert, M.H.1    Young, K.A.2    Hicks, P.B.3
  • 149
    • 33846986313 scopus 로고    scopus 로고
    • A 12-week, double-blind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics for the cognitive impairments in chronic schizophrenia
    • Lee SW, Lee JG, Lee BJ, Kim YH. A 12-week, double-blind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics for the cognitive impairments in chronic schizophrenia. Int. Clin. Psychopharmacol. 22(2), 63-68 (2007).
    • (2007) Int. Clin. Psychopharmacol. , vol.22 , Issue.2 , pp. 63-68
    • Lee, S.W.1    Lee, J.G.2    Lee, B.J.3    Kim, Y.H.4
  • 150
    • 46249116680 scopus 로고    scopus 로고
    • High-dose galantamine augmentation inferior to placebo on attention, inhibitory control and working memory performance in nonsmokers with schizophrenia
    • Dyer MA, Freudenreich O, Culhane MA et al. High-dose galantamine augmentation inferior to placebo on attention, inhibitory control and working memory performance in nonsmokers with schizophrenia. Schizophr. Res. 102(1-3), 88-95 (2008).
    • (2008) Schizophr. Res. , vol.102 , Issue.1-3 , pp. 88-95
    • Dyer, M.A.1    Freudenreich, O.2    Culhane, M.A.3
  • 151
    • 67749116340 scopus 로고    scopus 로고
    • The effects of galantamine on psychopathology in chronic stable schizophrenia
    • Conley RR, Boggs DL, Kelly DL et al. The effects of galantamine on psychopathology in chronic stable schizophrenia. Clin. Neuropharmacol. 32(2), 69-74 (2009).
    • (2009) Clin. Neuropharmacol. , vol.32 , Issue.2 , pp. 69-74
    • Conley, R.R.1    Boggs, D.L.2    Kelly, D.L.3
  • 152
    • 78951485005 scopus 로고    scopus 로고
    • Galantamine augmentation of long-acting injectable risperidone for cognitive impairments in chronic schizophrenia
    • Lindenmayer JP, Khan A. Galantamine augmentation of long-acting injectable risperidone for cognitive impairments in chronic schizophrenia. Schizophr. Res. 125(2-3), 267-277 (2011).
    • (2011) Schizophr. Res. , vol.125 , Issue.2-3 , pp. 267-277
    • Lindenmayer, J.P.1    Khan, A.2
  • 153
    • 72849132183 scopus 로고    scopus 로고
    • Improvement of negative and positive symptoms in treatment-refractory schizophrenia: A double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine
    • de Lucena D, Fernandes BS, Berk M et al. Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine. J. Clin. Psychiatry 70(10), 1416-1423 (2009).
    • (2009) J. Clin. Psychiatry , vol.70 , Issue.10 , pp. 1416-1423
    • De Lucena, D.1    Fernandes, B.S.2    Berk, M.3
  • 154
    • 62349116484 scopus 로고    scopus 로고
    • A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia
    • Lieberman JA, Papadakis K, Csernansky J et al. A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia. Neuropsychopharmacology 34(5), 1322-1329 (2009).
    • (2009) Neuropsychopharmacology , vol.34 , Issue.5 , pp. 1322-1329
    • Lieberman, J.A.1    Papadakis, K.2    Csernansky, J.3
  • 155
    • 33745378627 scopus 로고    scopus 로고
    • Cognitive effects of adjunctive 24-weeks Rivastigmine treatment to antipsychotics in schizophrenia: A randomized, placebo-controlled, double-blind investigation
    • DOI 10.1016/j.schres.2006.03.037, PII S092099640600096X
    • Sharma T, Reed C, Aasen I, Kumari V. Cognitive effects of adjunctive 24-weeks Rivastigmine treatment to antipsychotics in schizophrenia: a randomized, placebo-controlled, double-blind investigation. Schizophr. Res. 85(1-3), 73-83 (2006). (Pubitemid 43947524)
    • (2006) Schizophrenia Research , vol.85 , Issue.1-3 , pp. 73-83
    • Sharma, T.1    Reed, C.2    Aasen, I.3    Kumari, V.4
  • 157
    • 57349167353 scopus 로고    scopus 로고
    • Subunit-selective modulation of GABA type A receptor neurotransmission and cognition in schizophrenia
    • Lewis DA, Cho RY, Carter CS et al. Subunit-selective modulation of GABA type A receptor neurotransmission and cognition in schizophrenia. Am. J. Psychiatry 165(12), 1585-1593 (2008).
    • (2008) Am. J. Psychiatry , vol.165 , Issue.12 , pp. 1585-1593
    • Lewis, D.A.1    Cho, R.Y.2    Carter, C.S.3
  • 158
    • 79951656529 scopus 로고    scopus 로고
    • A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia
    • Buchanan RW, Keefe RS, Lieberman JA et al. A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia. Biol. Psychiatry 69(5), 442-449 (2011).
    • (2011) Biol. Psychiatry , vol.69 , Issue.5 , pp. 442-449
    • Buchanan, R.W.1    Keefe, R.S.2    Lieberman, J.A.3
  • 159
    • 0029658545 scopus 로고    scopus 로고
    • Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia
    • Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Horowitz A, Kelly D. Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. Br. J. Psychiatry 169(5), 610-617 (1996).
    • (1996) Br. J. Psychiatry , vol.169 , Issue.5 , pp. 610-617
    • Heresco-Levy, U.1    Javitt, D.C.2    Ermilov, M.3    Mordel, C.4    Horowitz, A.5    Kelly, D.6
  • 161
    • 0032955821 scopus 로고    scopus 로고
    • Effect of clozapine and adjunctive high-dose glycine in treatment- resistant schizophrenia
    • Potkin SG, Jin Y, Bunney BG, Costa J, Gulasekaram B. Effect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia. Am. J. Psychiatry 156(1), 145-147 (1999). (Pubitemid 29034896)
    • (1999) American Journal of Psychiatry , vol.156 , Issue.1 , pp. 145-147
    • Potkin, S.G.1    Jin, Y.2    Bunney, B.G.3    Costa, J.4    Gulasekaram, B.5
  • 162
    • 0034058017 scopus 로고    scopus 로고
    • Placebo-controlled trial of glycine added to clozapine in schizophrenia
    • DOI 10.1176/appi.ajp.157.5.826
    • Evins AE, Fitzgerald SM, Wine L, Rosselli R, Goff DC. Placebo-controlled trial of glycine added to clozapine in schizophrenia. Am. J. Psychiatry 157(5), 826-828 (2000). (Pubitemid 30249667)
    • (2000) American Journal of Psychiatry , vol.157 , Issue.5 , pp. 826-828
    • Evins, A.E.1    Fitzgerald, S.M.2    Wine, L.3    Rosselli, R.4    Goff, D.C.5
  • 164
    • 1442333154 scopus 로고    scopus 로고
    • High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia
    • DOI 10.1016/S0006-3223(03)00707-8, PII S0006322303007078
    • Heresco-Levy U, Ermilov M, Lichtenberg P, Bar G, Javitt DC. High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia. Biol. Psychiatry 55(2), 165-171 (2004). (Pubitemid 38367720)
    • (2004) Biological Psychiatry , vol.55 , Issue.2 , pp. 165-171
    • Heresco-Levy, U.1    Ermilov, M.2    Lichtenberg, P.3    Bar, G.4    Javitt, D.C.5
  • 167
    • 27744529018 scopus 로고    scopus 로고
    • Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: A randomized, double-blind, placebo-controlled study
    • DOI 10.1001/archpsyc.62.11.1196
    • Lane HY, Chang YC, Liu YC, Chiu CC, Tsai GE. Sarcosine or d-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study. Arch. Gen. Psychiatry 62(11), 1196-1204 (2005). (Pubitemid 41586919)
    • (2005) Archives of General Psychiatry , vol.62 , Issue.11 , pp. 1196-1204
    • Lane, H.-Y.1    Chang, Y.-C.2    Liu, Y.-C.3    Chiu, C.-C.4    Tsai, G.E.5
  • 168
    • 77953545879 scopus 로고    scopus 로고
    • Arandomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and d-serine add-on treatment for schizophrenia
    • Lane HY, Lin CH, Huang YJ et al. A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and d-serine add-on treatment for schizophrenia. Int. J. Neuropsychopharmacol. 13(4), 451-460 (2010).
    • (2010) Int. J. Neuropsychopharmacol. , vol.13 , Issue.4 , pp. 451-460
    • Lane, H.Y.1    Lin, C.H.2    Huang, Y.J.3
  • 169
    • 33748751382 scopus 로고    scopus 로고
    • Glycine transporter i inhibitor N-methylglycine (sarcosine) added to clozapine for the treatment of schizophrenia
    • Lane HY, Huang CL, Wu PL et al. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia. Biol. Psychiatry 60(6), 645-649 (2006).
    • (2006) Biol. Psychiatry , vol.60 , Issue.6 , pp. 645-649
    • Lane, H.Y.1    Huang, C.L.2    Wu, P.L.3
  • 170
    • 0032974130 scopus 로고    scopus 로고
    • D-cycloserine increases positive symptoms in chronic schizophrenic patients when administered in addition to antipsychotics: A double-blind, parallel, placebo-controlled study
    • DOI 10.1016/S0893-133X(99)00014-7, PII S0893133X99000147
    • van Berckel BN, Evenblij CN, van Loon BJ et al. d-cycloserine increases positive symptoms in chronic schizophrenic patients when administered in addition to antipsychotics: a double-blind, parallel, placebo-controlled study. Neuropsychopharmacology 21(2), 203-210 (1999). (Pubitemid 29304581)
    • (1999) Neuropsychopharmacology , vol.21 , Issue.2 , pp. 203-210
    • Van Berckel, B.N.M.1    Evenblij, C.N.2    Van Loon, B.J.A.M.3    Maas, M.F.4    Van Der Geld, M.A.M.5    Wynne, H.J.6    Van Ree, J.M.7    Kahn, R.S.8
  • 171
    • 0036184549 scopus 로고    scopus 로고
    • Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia
    • DOI 10.1176/appi.ajp.159.3.480
    • Heresco-Levy U, Ermilov M, Shimoni J, Shapira B, Silipo G, Javitt DC. Placebo-controlled trial of d-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia. Am. J. Psychiatry 159(3), 480-482 (2002). (Pubitemid 34184748)
    • (2002) American Journal of Psychiatry , vol.159 , Issue.3 , pp. 480-482
    • Heresco-Levy, U.1    Ermilov, M.2    Shimoni, J.3    Shapira, B.4    Silipo, G.5    Javitt, D.C.6
  • 173
    • 56049099989 scopus 로고    scopus 로고
    • Once-weekly d-cycloserine effects on negative symptoms and cognition in schizophrenia: An exploratory study
    • Goff DC, Cather C, Gottlieb JD et al. Once-weekly d-cycloserine effects on negative symptoms and cognition in schizophrenia: an exploratory study. Schizophr. Res. 106(2-3), 320-327 (2008).
    • (2008) Schizophr. Res. , vol.106 , Issue.2-3 , pp. 320-327
    • Goff, D.C.1    Cather, C.2    Gottlieb, J.D.3
  • 174
    • 32144442536 scopus 로고    scopus 로고
    • D-alanine added to antipsychotics for the treatment of schizophrenia
    • DOI 10.1016/j.biopsych.2005.06.032, PII S0006322305008462
    • Tsai GE, Yang P, Chang YC, Chong MY. d-alanine added to antipsychotics for the treatment of schizophrenia. Biol. Psychiatry 59(3), 230-234 (2006). (Pubitemid 43208969)
    • (2006) Biological Psychiatry , vol.59 , Issue.3 , pp. 230-234
    • Tsai, G.E.1    Yang, P.2    Chang, Y.-C.3    Chong, M.-Y.4
  • 176
    • 38149132338 scopus 로고    scopus 로고
    • A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia
    • Goff DC, Lamberti JS, Leon AC et al. A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia. Neuropsychopharmacology 33(3), 465-472 (2008).
    • (2008) Neuropsychopharmacology , vol.33 , Issue.3 , pp. 465-472
    • Goff, D.C.1    Lamberti, J.S.2    Leon, A.C.3
  • 177
    • 0035280803 scopus 로고    scopus 로고
    • Estrogen-a potential treatment for schizophrenia
    • Kulkarni J, Riedel A, de Castella AR et al. Estrogen-a potential treatment for schizophrenia. Schizophr. Res. 48(1), 137-144 (2001).
    • (2001) Schizophr. Res. , vol.48 , Issue.1 , pp. 137-144
    • Kulkarni, J.1    Riedel, A.2    De Castella, A.R.3
  • 179
    • 0037312851 scopus 로고    scopus 로고
    • Dehydroepiandrosterone augmentation in the management of negative, depressive, and anxiety symptoms in schizophrenia
    • DOI 10.1001/archpsyc.60.2.133
    • Strous RD, Maayan R, Lapidus R et al. Dehydroepiandrosterone augmentation in the management of negative, depressive, and anxiety symptoms in schizophrenia. Arch. Gen. Psychiatry 60(2), 133-141 (2003). (Pubitemid 36173119)
    • (2003) Archives of General Psychiatry , vol.60 , Issue.2 , pp. 133-141
    • Strous, R.D.1    Maayan, R.2    Lapidus, R.3    Stryjer, R.4    Lustig, M.5    Kotler, M.6    Weizman, A.7
  • 180
    • 33644874630 scopus 로고    scopus 로고
    • Hormonal profile effects following dehydroepiandrosterone (DHEA) administration to schizophrenic patients
    • DOI 10.1097/01.wnf.0000188716.25211.58, PII 0000282620051100000003
    • Strous RD, Maayan R, Kotler M, Weizman A. Hormonal profile effects following dehydroepiandrosterone (DHEA) administration to schizophrenic patients. Clin. Neuropharmacol. 28(6), 265-269 (2005). (Pubitemid 44378615)
    • (2005) Clinical Neuropharmacology , vol.28 , Issue.6 , pp. 265-269
    • Strous, R.D.1    Maayan, R.2    Kotler, M.3    Weizman, A.4
  • 181
    • 33748745743 scopus 로고    scopus 로고
    • Improvement of sustained attention and visual and movement skills, but not clinical symptoms, after dehydroepiandrosterone augmentation in schizophrenia: A randomized, double-blind, placebo-controlled, crossover trial
    • DOI 10.1097/01.jcp.0000237942.50270.35, PII 0000471420061000000010
    • Ritsner MS, Gibel A, Ratner Y, Tsinovoy G, Strous RD. Improvement of sustained attention and visual and movement skills, but not clinical symptoms, after dehydroepiandrosterone augmentation in schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial. J. Clin. Psychopharmacol. 26(5), 495-499 (2006). (Pubitemid 44401470)
    • (2006) Journal of Clinical Psychopharmacology , vol.26 , Issue.5 , pp. 495-499
    • Ritsner, M.S.1    Gibel, A.2    Ratner, Y.3    Tsinovoy, G.4    Strous, R.D.5
  • 182
    • 33847048555 scopus 로고    scopus 로고
    • Analysis of clinical symptomatology, extrapyramidal symptoms and neurocognitive dysfunction following dehydroepiandrosterone (DHEA) administration in olanzapine treated schizophrenia patients: A randomized, double-blind placebo controlled trial
    • DOI 10.1016/j.psyneuen.2006.11.002, PII S030645300600196X
    • Strous RD, Stryjer R, Maayan R et al. Analysis of clinical symptomatology, extrapyramidal symptoms and neurocognitive dysfunction following dehydroepiandrosterone (DHEA) administration in olanzapine treated schizophrenia patients: a randomized, double-blind placebo controlled trial. Psychoneuroendocrinology 32(2), 96-105 (2007). (Pubitemid 46274013)
    • (2007) Psychoneuroendocrinology , vol.32 , Issue.2 , pp. 96-105
    • Strous, R.D.1    Stryjer, R.2    Maayan, R.3    Gal, G.4    Viglin, D.5    Katz, E.6    Eisner, D.7    Weizman, A.8
  • 183
    • 54449085337 scopus 로고    scopus 로고
    • Short-term testosterone augmentation in male schizophrenics: A randomized, double-blind, placebo-controlled trial
    • Ko YH, Lew YM, Jung SW et al. Short-term testosterone augmentation in male schizophrenics: a randomized, double-blind, placebo-controlled trial. J. Clin. Psychopharmacol. 28(4), 375-383 (2008).
    • (2008) J. Clin. Psychopharmacol. , vol.28 , Issue.4 , pp. 375-383
    • Ko, Y.H.1    Lew, Y.M.2    Jung, S.W.3
  • 184
    • 48949095082 scopus 로고    scopus 로고
    • Estrogen in severe mental illness: A potential new treatment approach
    • Kulkarni J, de Castella A, Fitzgerald PB et al. Estrogen in severe mental illness: a potential new treatment approach. Arch. Gen. Psychiatry 65(8), 955-960 (2008).
    • (2008) Arch. Gen. Psychiatry , vol.65 , Issue.8 , pp. 955-960
    • Kulkarni, J.1    De Castella, A.2    Fitzgerald, P.B.3
  • 185
    • 67449123074 scopus 로고    scopus 로고
    • Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia
    • Marx CE, Keefe RS, Buchanan RW et al. Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia. Neuropsychopharmacology 34(8), 1885-1903 (2009).
    • (2009) Neuropsychopharmacology , vol.34 , Issue.8 , pp. 1885-1903
    • Marx, C.E.1    Keefe, R.S.2    Buchanan, R.W.3
  • 186
    • 77955575168 scopus 로고    scopus 로고
    • Piloting the effective therapeutic dose of adjunctive selective estrogen receptor modulator treatment in postmenopausal women with schizophrenia
    • Kulkarni J, Gurvich C, Lee SJ et al. Piloting the effective therapeutic dose of adjunctive selective estrogen receptor modulator treatment in postmenopausal women with schizophrenia. Psychoneuroendocrinology 35(8), 1142-1147 (2010).
    • (2010) Psychoneuroendocrinology , vol.35 , Issue.8 , pp. 1142-1147
    • Kulkarni, J.1    Gurvich, C.2    Lee, S.J.3
  • 187
    • 74549188501 scopus 로고    scopus 로고
    • Pregnenolone and dehydroepiandrosterone as an adjunctive treatment in schizophrenia and schizoaffective disorder: An 8-week, double-blind, randomized, controlled, 2-center, parallel-group trial
    • Ritsner MS, Gibel A, Shleifer T et al. Pregnenolone and dehydroepiandrosterone as an adjunctive treatment in schizophrenia and schizoaffective disorder: an 8-week, double-blind, randomized, controlled, 2-center, parallel-group trial. J. Clin. Psychiatry 71(10), 1351-1362 (2010).
    • (2010) J. Clin. Psychiatry , vol.71 , Issue.10 , pp. 1351-1362
    • Ritsner, M.S.1    Gibel, A.2    Shleifer, T.3
  • 188
    • 0035190361 scopus 로고    scopus 로고
    • A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia
    • DOI 10.1176/appi.ajp.158.12.2071
    • Fenton WS, Dickerson F, Boronow J, Hibbeln JR, Knable M. A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia. Am. J. Psychiatry 158(12), 2071-2074 (2001). (Pubitemid 33104119)
    • (2001) American Journal of Psychiatry , vol.158 , Issue.12 , pp. 2071-2074
    • Fenton, W.S.1    Dickerson, F.2    Boronow, J.3    Hibbeln, J.R.4    Knable, M.5
  • 189
    • 0036712807 scopus 로고    scopus 로고
    • Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia
    • DOI 10.1176/appi.ajp.159.9.1596
    • Emsley R, Myburgh C, Oosthuizen P, van Rensburg SJ. Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia. Am. J. Psychiatry 159(9), 1596-1598 (2002). (Pubitemid 35006744)
    • (2002) American Journal of Psychiatry , vol.159 , Issue.9 , pp. 1596-1598
    • Emsley, R.1    Myburgh, C.2    Oosthuizen, P.3    Van Rensburg, S.J.4
  • 190
    • 0027200994 scopus 로고
    • Beneficial effects of nalmefene augmentation in neuroleptic-stabilized schizophrenic patients
    • Rapaport MH, Wolkowitz O, Kelsoe JR, Pato C, Konicki PE, Pickar D. Beneficial effects of nalmefene augmentation in neuroleptic-stabilized schizophrenic patients. Neuropsychopharmacology 9(2), 111-115 (1993). (Pubitemid 23275836)
    • (1993) Neuropsychopharmacology , vol.9 , Issue.2 , pp. 111-115
    • Rapaport, M.H.1    Wolkowitz, O.2    Kelsoe, J.R.3    Pato, C.4    Konicki, P.E.5    Pickar, D.6
  • 194
    • 77956932186 scopus 로고    scopus 로고
    • Adjunctive intranasal oxytocin reduces symptoms in schizophrenia patients
    • Feifel D, Macdonald K, Nguyen A et al. Adjunctive intranasal oxytocin reduces symptoms in schizophrenia patients. Biol. Psychiatry 68(7), 678-680 (2010).
    • (2010) Biol. Psychiatry , vol.68 , Issue.7 , pp. 678-680
    • Feifel, D.1    MacDonald, K.2    Nguyen, A.3
  • 196
    • 13444259750 scopus 로고    scopus 로고
    • Beneficial antipsychotic effects of allopurinol as add-on therapy for schizophrenia: A double blind, randomized and placebo controlled trial
    • DOI 10.1016/j.pnpbp.2004.11.008
    • Akhondzadeh S, Safarcherati A, Amini H. Beneficial antipsychotic effects of allopurinol as add-on therapy for schizophrenia: a double blind, randomized and placebo controlled trial. Prog. Neuropsychopharmacol. Biol. Psychiatry 29(2), 253-259 (2005). (Pubitemid 40202911)
    • (2005) Progress in Neuro-Psychopharmacology and Biological Psychiatry , vol.29 , Issue.2 , pp. 253-259
    • Akhondzadeh, S.1    Safarcherati, A.2    Amini, H.3
  • 197
    • 14644406149 scopus 로고    scopus 로고
    • A clinical trial of adjuvant allopurinol therapy for moderately refractory schizophrenia
    • Brunstein MG, Ghisolfi ES, Ramos FL, Lara DR. A clinical trial of adjuvant allopurinol therapy for moderately refractory schizophrenia. J. Clin. Psychiatry 66(2), 213-219 (2005). (Pubitemid 40314328)
    • (2005) Journal of Clinical Psychiatry , vol.66 , Issue.2 , pp. 213-219
    • Brunstein, M.G.1    Ghisolfi, E.S.2    Ramos, F.L.P.3    Lara, D.R.4
  • 199
    • 62649140849 scopus 로고    scopus 로고
    • A double-blind trial of adjunctive allopurinol for schizophrenia
    • Dickerson FB, Stallings CR, Origoni AE et al. A double-blind trial of adjunctive allopurinol for schizophrenia. Schizophr. Res. 109(1-3), 66-69 (2009).
    • (2009) Schizophr. Res. , vol.109 , Issue.1-3 , pp. 66-69
    • Dickerson, F.B.1    Stallings, C.R.2    Origoni, A.E.3
  • 201
    • 34548189417 scopus 로고    scopus 로고
    • 1A partial agonist, on cognitive function in schizophrenia: A randomized, double-blind, placebo-controlled study
    • DOI 10.1016/j.schres.2007.06.008, PII S0920996407002630
    • Sumiyoshi T, Park S, Jayathilake K, Roy A, Ertugrul A, Meltzer HY. Effect of buspirone, a serotonin1A partial agonist, on cognitive function in schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr. Res. 95(1-3), 158-168 (2007). (Pubitemid 47313647)
    • (2007) Schizophrenia Research , vol.95 , Issue.1-3 , pp. 158-168
    • Sumiyoshi, T.1    Park, S.2    Jayathilake, K.3    Roy, A.4    Ertugrul, A.5    Meltzer, H.Y.6
  • 202
    • 70349544018 scopus 로고    scopus 로고
    • Treatment of cognitive dysfunction in chronic schizophrenia by augmentation of atypical antipsychotics with buspirone, a partial 5-HT1A receptor agonist
    • Piskuli D, Olver JS, Maruff P, Norman TR. Treatment of cognitive dysfunction in chronic schizophrenia by augmentation of atypical antipsychotics with buspirone, a partial 5-HT1A receptor agonist. Hum. Psychopharmacol. 24(6), 437-446 (2009).
    • (2009) Hum. Psychopharmacol. , vol.24 , Issue.6 , pp. 437-446
    • Piskuli, D.1    Olver, J.S.2    Maruff, P.3    Norman, T.R.4
  • 203
    • 78649371717 scopus 로고    scopus 로고
    • A double-blind, randomized, and placebo-controlled trial of buspirone added to risperidone in patients with chronic schizophrenia
    • Ghaleiha A, Noorbala AA, Farnaghi F, Hajiazim M, Akhondzadeh S. A double-blind, randomized, and placebo-controlled trial of buspirone added to risperidone in patients with chronic schizophrenia. J. Clin. Psychopharmacol. 30(6), 678-682 (2010).
    • (2010) J. Clin. Psychopharmacol. , vol.30 , Issue.6 , pp. 678-682
    • Ghaleiha, A.1    Noorbala, A.A.2    Farnaghi, F.3    Hajiazim, M.4    Akhondzadeh, S.5
  • 204
    • 33750609681 scopus 로고    scopus 로고
    • Beneficial effects of ondansetron as an adjunct to haloperidol for chronic, treatment-resistant schizophrenia: A double-blind, randomized, placebo-controlled study
    • DOI 10.1016/j.schres.2006.07.010, PII S0920996406003173
    • Zhang ZJ, Kang WH, Li Q, Wang XY, Yao SM, Ma AQ. Beneficial effects of ondansetron as an adjunct to haloperidol for chronic, treatment-resistant schizophrenia: a double-blind, randomized, placebo-controlled study. Schizophr. Res. 88(1-3), 102-110 (2006). (Pubitemid 44693244)
    • (2006) Schizophrenia Research , vol.88 , Issue.1-3 , pp. 102-110
    • Zhang, Z.-J.1    Kang, W.-H.2    Li, Q.3    Wang, X.-Y.4    Yao, S.-M.5    Ma, A.-Q.6
  • 205
    • 58349098103 scopus 로고    scopus 로고
    • Added ondansetron for stable schizophrenia: A double blind, placebo controlled trial
    • Akhondzadeh S, Mohammadi N, Noroozian M et al. Added ondansetron for stable schizophrenia: a double blind, placebo controlled trial. Schizophr. Res. 107(2-3), 206-212 (2009).
    • (2009) Schizophr. Res. , vol.107 , Issue.2-3 , pp. 206-212
    • Akhondzadeh, S.1    Mohammadi, N.2    Noroozian, M.3
  • 207
    • 34249661792 scopus 로고    scopus 로고
    • A randomized, double-blind, placebo-controlled trial of modafinil for negative symptoms in schizophrenia
    • Pierre JM, Peloian JH, Wirshing DA, Wirshing WC, Marder SR. A randomized, double-blind, placebo-controlled trial of modafinil for negative symptoms in schizophrenia. J. Clin. Psychiatry 68(5), 705-710 (2007). (Pubitemid 46841853)
    • (2007) Journal of Clinical Psychiatry , vol.68 , Issue.5 , pp. 705-710
    • Pierre, J.M.1    Peloian, J.H.2    Wirshing, D.A.3    Wirshing, W.C.4    Marder, S.R.5
  • 208
    • 74549156560 scopus 로고    scopus 로고
    • Modafinil for clozapine-treated schizophrenia patients: A double-blind, placebo-controlled pilot trial
    • Freudenreich O, Henderson DC, Macklin EA et al. Modafinil for clozapine-treated schizophrenia patients: a double-blind, placebo-controlled pilot trial. J. Clin. Psychiatry 70(12), 1674-1680 (2009).
    • (2009) J. Clin. Psychiatry , vol.70 , Issue.12 , pp. 1674-1680
    • Freudenreich, O.1    Henderson, D.C.2    MacKlin, E.A.3
  • 209
    • 78649773228 scopus 로고    scopus 로고
    • Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: A 4-week, double-blind, placebo-controlled study
    • Kane JM, D'Souza DC, Patkar AA et al. Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: a 4-week, double-blind, placebo-controlled study. J. Clin. Psychiatry 71(11), 1475-1481 (2010).
    • (2010) J. Clin. Psychiatry , vol.71 , Issue.11 , pp. 1475-1481
    • Kane, J.M.1    D'Souza, D.C.2    Patkar, A.A.3
  • 210
    • 26944441259 scopus 로고    scopus 로고
    • A double-blind, cross-over comparison of the effects of amantadine or placebo on visuomotor and cognitive function in medicated schizophrenia patients
    • DOI 10.1097/00004850-200511000-00007
    • Silver H, Goodman C, Isakov V, Knoll G, Modai I. A double-blind, cross-over comparison of the effects of amantadine or placebo on visuomotor and cognitive function in medicated schizophrenia patients. Int. Clin. Psychopharmacol. 20(6), 319-326 (2005). (Pubitemid 41475322)
    • (2005) International Clinical Psychopharmacology , vol.20 , Issue.6 , pp. 319-326
    • Silver, H.1    Goodman, C.2    Isakov, V.3    Knoll, G.4    Modai, I.5
  • 211
    • 34347351060 scopus 로고    scopus 로고
    • Lack of efficacy of 5 grams daily of creatine in schizophrenia: A randomized, double-blind, placebo-controlled trial
    • Kaptsan A, Odessky A, Osher Y, Levine J. Lack of efficacy of 5 grams daily of creatine in schizophrenia: a randomized, double-blind, placebo-controlled trial. J. Clin. Psychiatry 68(6), 881-884 (2007). (Pubitemid 47015487)
    • (2007) Journal of Clinical Psychiatry , vol.68 , Issue.6 , pp. 881-884
    • Kaptsan, A.1    Odessky, A.2    Osher, Y.3    Levine, J.4
  • 213
    • 0029317806 scopus 로고
    • Cyproheptadine augmentation of haloperidol in chronic schizophrenic patients: A double-blind placebo-controlled study
    • Lee HS, Song DH, Kim JH, Lee YM, Han ES, Yoo KJ. Cyproheptadine augmentation of haloperidol in chronic schizophrenic patients: a double-blind placebo-controlled study. Int. Clin. Psychopharmacol. 10(2), 67-72 (1995).
    • (1995) Int. Clin. Psychopharmacol. , vol.10 , Issue.2 , pp. 67-72
    • Lee, H.S.1    Song, D.H.2    Kim, J.H.3    Lee, Y.M.4    Han, E.S.5    Yoo, K.J.6
  • 215
    • 77649112679 scopus 로고    scopus 로고
    • A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia
    • Levkovitz Y, Mendlovich S, Riwkes S et al. A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J. Clin. Psychiatry 71(2), 138-149 (2010).
    • (2010) J. Clin. Psychiatry , vol.71 , Issue.2 , pp. 138-149
    • Levkovitz, Y.1    Mendlovich, S.2    Riwkes, S.3
  • 216
    • 79551525420 scopus 로고    scopus 로고
    • L-theanine relieves positive, activation, and anxiety symptoms in patients with schizophrenia and schizoaffective disorder: An 8-week, randomized, double-blind, placebo-controlled, 2-center study
    • Ritsner MS, Miodownik C, Ratner Y et al. l-theanine relieves positive, activation, and anxiety symptoms in patients with schizophrenia and schizoaffective disorder: an 8-week, randomized, double-blind, placebo-controlled, 2-center study. J. Clin. Psychiatry 72(1), 34-42 (2011).
    • (2011) J. Clin. Psychiatry , vol.72 , Issue.1 , pp. 34-42
    • Ritsner, M.S.1    Miodownik, C.2    Ratner, Y.3
  • 217
    • 48749112603 scopus 로고    scopus 로고
    • N-acetyl cysteine as a glutathione precursor for schizophrenia - A double-blind, randomized, placebo-controlled trial
    • Berk M, Copolov D, Dean O et al. N-acetyl cysteine as a glutathione precursor for schizophrenia-a double-blind, randomized, placebo-controlled trial. Biol. Psychiatry 64(5), 361-368 (2008).
    • (2008) Biol. Psychiatry , vol.64 , Issue.5 , pp. 361-368
    • Berk, M.1    Copolov, D.2    Dean, O.3
  • 220
    • 57049171917 scopus 로고    scopus 로고
    • Improvement of aggressive behavior and quality of life impairment following S-adenosyl-methionine (SAM-e) augmentation in schizophrenia
    • Strous RD, Ritsner MS, Adler S et al. Improvement of aggressive behavior and quality of life impairment following S-adenosyl-methionine (SAM-e) augmentation in schizophrenia. Eur. Neuropsychopharmacol. 19(1), 14-22 (2009).
    • (2009) Eur. Neuropsychopharmacol. , vol.19 , Issue.1 , pp. 14-22
    • Strous, R.D.1    Ritsner, M.S.2    Adler, S.3
  • 221
    • 79952487439 scopus 로고    scopus 로고
    • Sildenafil adjunctive therapy to risperidone in the treatment of the negative symptoms of schizophrenia: A double-blind randomized placebo-controlled trial
    • Akhondzadeh S, Ghayyoumi R, Rezaei F et al. Sildenafil adjunctive therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled trial. Psychopharmacology (Berl.) 213(4), 809-815 (2011).
    • (2011) Psychopharmacology (Berl.) , vol.213 , Issue.4 , pp. 809-815
    • Akhondzadeh, S.1    Ghayyoumi, R.2    Rezaei, F.3
  • 222
    • 77956864079 scopus 로고    scopus 로고
    • Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: Meta-analysis
    • Singh SP, Singh V, Kar N, Chan K. Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: meta-analysis. Br. J. Psychiatry 197(3), 174-179 (2010).
    • (2010) Br. J. Psychiatry , vol.197 , Issue.3 , pp. 174-179
    • Singh, S.P.1    Singh, V.2    Kar, N.3    Chan, K.4
  • 223
    • 80755140872 scopus 로고    scopus 로고
    • Chapter 15: Psychopharmacology and electroconvulsive therapy
    • Simon RI, Tardiff K (Eds), American Psychiatric Publishing, Inc., Arlington, VA, USA
    • Citrome L. Chapter 15: psychopharmacology and electroconvulsive therapy. In: Textbook of Violence Assessmentand Management. Simon RI, Tardiff K (Eds). American Psychiatric Publishing, Inc., Arlington, VA, USA, 301-323 (2008).
    • (2008) Textbook of Violence Assessmentand Management , pp. 301-323
    • Citrome, L.1
  • 224
    • 0033060951 scopus 로고    scopus 로고
    • Cognitive-behavioral therapy and clozapine for clients with treatment- refractory schizophrenia
    • Pinto A, La Pia S, Mennella R, Giorgio D, DeSimone L. Cognitive-behavioral therapy and clozapine for clients with treatment-refractory schizophrenia. Psychiatr. Serv. 50(7), 901-904 (1999). (Pubitemid 29309860)
    • (1999) Psychiatric Services , vol.50 , Issue.7 , pp. 901-904
    • Pinto, A.1    La Pia, S.2    Mennella, R.3    Giorgio, D.4    DeSimone, L.5
  • 225
    • 17144382810 scopus 로고    scopus 로고
    • Cognitive-behavioural therapy for refractory psychotic symptoms of schizophrenia resistant to atypical antipsychotic medication: Randomised controlled trial
    • DOI 10.1192/bjp.186.4.324
    • Valmaggia LR, van der Gaag M, Tarrier N, Pijnenborg M, Slooff CJ. Cognitive-behavioural therapy for refractory psychotic symptoms of schizophrenia resistant to atypical antipsychotic medication. Randomised controlled trial. Br. J. Psychiatry 186, 324-330 (2005). (Pubitemid 40524012)
    • (2005) British Journal of Psychiatry , vol.186 , Issue.APR. , pp. 324-330
    • Valmaggia, L.R.1    Van Der Gaag, M.2    Tarrier, N.3    Pijnenborg, M.4    Slooff, C.J.5
  • 226
    • 73449143556 scopus 로고    scopus 로고
    • A preliminary controlled trial of cognitive behavioral therapy in clozapine-resistant schizophrenia
    • Barretto EM, Kayo M, Avrichir BS et al. A preliminary controlled trial of cognitive behavioral therapy in clozapine-resistant schizophrenia. J. Nerv. Ment. Dis. 197(11), 865-868 (2009).
    • (2009) J. Nerv. Ment. Dis. , vol.197 , Issue.11 , pp. 865-868
    • Barretto, E.M.1    Kayo, M.2    Avrichir, B.S.3
  • 227
    • 0042203177 scopus 로고    scopus 로고
    • Continuation ECT in treatment-resistant schizophrenia: A controlled study
    • Chanpattana W, Chakrabhand ML, Sackeim HA et al. Continuation ECT in treatment-resistant schizophrenia: a controlled study. J. ECT 15(3), 178-192 (1999).
    • (1999) J. ECT , vol.15 , Issue.3 , pp. 178-192
    • Chanpattana, W.1    Chakrabhand, M.L.2    Sackeim, H.A.3
  • 228
    • 33749334000 scopus 로고    scopus 로고
    • Efficacy of Electroconvulsive Therapy in Treatment Resistant Schizophrenia: A double-blind study
    • Goswami U, Kumar U, Singh B. Efficacy of electroconvulsive therapy in treatment resistant schizophrenia: a double blind study. Indian J. Psychiatry 45(1), 26-29 (2003). (Pubitemid 36657671)
    • (2003) Indian Journal of Psychiatry , vol.45 , Issue.1 , pp. 26-29
    • Goswami, U.1    Kumar, U.2    Singh, B.3
  • 231
    • 13844266333 scopus 로고    scopus 로고
    • A double blind study showing that two weeks of daily repetitive TMS over the left or right temporoparietal cortex reduces symptoms in patients with schizophrenia who are having treatment-refractory auditory hallucinations
    • DOI 10.1016/j.neulet.2004.11.048
    • Lee SH, Kim W, Chung YC et al. A double blind study showing that two weeks of daily repetitive TMS over the left or right temporoparietal cortex reduces symptoms in patients with schizophrenia who are having treatment-refractory auditory hallucinations. Neurosci. Lett. 376(3), 177-181 (2005). (Pubitemid 40255305)
    • (2005) Neuroscience Letters , vol.376 , Issue.3 , pp. 177-181
    • Lee, S.-H.1    Kim, W.2    Chung, Y.-C.3    Jung, K.-H.4    Bahk, W.-M.5    Jun, T.-Y.6    Kim, K.-S.7    George, M.S.8    Chae, J.-H.9
  • 233
    • 34249340096 scopus 로고    scopus 로고
    • Repetitive transcranial magnetic stimulation for negative symptoms of schizophrenia: A randomized controlled pilot study
    • DOI 10.1016/j.schres.2007.03.016, PII S0920996407001478
    • Mogg A, Purvis R, Eranti S et al. Repetitive transcranial magnetic stimulation for negative symptoms of schizophrenia: a randomized controlled pilot study. Schizophr. Res. 93(1-3), 221-228 (2007). (Pubitemid 46817960)
    • (2007) Schizophrenia Research , vol.93 , Issue.1-3 , pp. 221-228
    • Mogg, A.1    Purvis, R.2    Eranti, S.3    Contell, F.4    Taylor, J.P.5    Nicholson, T.6    Brown, R.G.7    McLoughlin, D.M.8
  • 234
    • 34548178664 scopus 로고    scopus 로고
    • Treatment of negative symptoms of schizophrenia using repetitive transcranial magnetic stimulation in a double-blind, randomized controlled study
    • DOI 10.1016/j.schres.2007.06.019, PII S0920996407002733
    • Prikryl R, Kasparek T, Sketakova S et al. Treatment of negative symptoms of schizophrenia using repetitive transcranial magnetic stimulation in a double-blind, randomized controlled study. Schizophr. Res. 95(1-3), 151-157 (2007). (Pubitemid 47313654)
    • (2007) Schizophrenia Research , vol.95 , Issue.1-3 , pp. 151-157
    • Prikryl, R.1    Kasparek, T.2    Skotakova, S.3    Ustohal, L.4    Kucerova, H.5    Ceskova, E.6
  • 236
    • 45949097437 scopus 로고    scopus 로고
    • A study of the effectiveness of bilateral transcranial magnetic stimulation in the treatment of the negative symptoms of schizophrenia
    • DOI 10.1016/j.brs.2007.08.001, PII S1935861X07000022
    • Fitzgerald PB, Herring S, Hoy K et al. A study of the effectiveness of bilateral transcranial magnetic stimulation in the treatment of the negative symptoms of schizophrenia. Brain Stimul. 1(1), 27-32 (2008). (Pubitemid 351966358)
    • (2008) Brain Stimulation , vol.1 , Issue.1 , pp. 27-32
    • Fitzgerald, P.B.1    Herring, S.2    Hoy, K.3    McQueen, S.4    Segrave, R.5    Kulkarni, J.6    Daskalakis, Z.J.7
  • 237
    • 43749112352 scopus 로고    scopus 로고
    • Repetitive transcranial magnetic stimulation (rTMS) as an augmentation treatment for the negative symptoms of schizophrenia: A 4-week randomized placebo controlled study
    • DOI 10.1016/j.brs.2008.01.001, PII S1935861X08000028
    • Schneider AL, Schneider TL, Stark H. Repetitive transcranial magnetic stimulation (rTMS) as an augmentation treatment for the negative symptoms of schizophrenia: a 4-week randomized placebo controlled study. Brain Stimul. 1(2), 106-111 (2008). (Pubitemid 351689965)
    • (2008) Brain Stimulation , vol.1 , Issue.2 , pp. 106-111
    • Schneider, A.L.1    Schneider, T.L.2    Stark, H.3
  • 238
    • 69849086472 scopus 로고    scopus 로고
    • Effects of bilateral repetitive transcranial magnetic stimulation on treatment resistant auditory-verbal hallucinations in schizophrenia: A randomized controlled trial
    • Vercammen A, Knegtering H, Bruggeman R et al. Effects of bilateral repetitive transcranial magnetic stimulation on treatment resistant auditory-verbal hallucinations in schizophrenia: a randomized controlled trial. Schizophr. Res. 114(1-3), 172-179 (2009).
    • (2009) Schizophr. Res. , vol.114 , Issue.1-3 , pp. 172-179
    • Vercammen, A.1    Knegtering, H.2    Bruggeman, R.3
  • 239
    • 79958249150 scopus 로고    scopus 로고
    • A pilot double-blind sham-controlled trial of repetitive transcranial magnetic stimulation for patients with refractory schizophrenia treated with clozapine
    • DOI: 10.1016/j.psychres.2010.11.022 Epub ahead of print
    • De Jesus DR, Gil A, Barbosa L et al. A pilot double-blind sham-controlled trial of repetitive transcranial magnetic stimulation for patients with refractory schizophrenia treated with clozapine. Psychiatry Res. DOI: 10.1016/j.psychres.2010.11.022 (2010) (Epub ahead of print).
    • (2010) Psychiatry Res.
    • De Jesus, D.R.1    Gil, A.2    Barbosa, L.3
  • 240
    • 33645542970 scopus 로고    scopus 로고
    • "Hitting" voices of schizophrenia patients may lastingly reduce persistent auditory hallucinations and their burden: 18-Month outcome of a randomized controlled trial
    • Jenner JA, Nienhuis FJ, van de Willige G, Wiersma D. "Hitting" voices of schizophrenia patients may lastingly reduce persistent auditory hallucinations and their burden: 18-month outcome of a randomized controlled trial. Can. J. Psychiatry 51(3), 169-177 (2006).
    • (2006) Can. J. Psychiatry , vol.51 , Issue.3 , pp. 169-177
    • Jenner, J.A.1    Nienhuis, F.J.2    Van De Willige, G.3    Wiersma, D.4
  • 241
    • 77958187804 scopus 로고    scopus 로고
    • Neuroplasticity-based cognitive training in schizophrenia: An interim report on the effects 6 months later
    • Fisher M, Holland C, Subramaniam K, Vinogradov S. Neuroplasticity-based cognitive training in schizophrenia: an interim report on the effects 6 months later. Schizophr. Bull. 36(4), 869-879 (2010).
    • (2010) Schizophr. Bull. , vol.36 , Issue.4 , pp. 869-879
    • Fisher, M.1    Holland, C.2    Subramaniam, K.3    Vinogradov, S.4
  • 242
    • 0037350926 scopus 로고    scopus 로고
    • Randomized controlled trial of occupational therapy in patients with treatment-resistant schizophrenia
    • Buchain PC, Vizzotto AD, Henna Neto J, Elkis H. Randomized controlled trial of occupational therapy in patients with treatment-resistant schizophrenia. Rev. Bras. Psiquiatr. 25(1), 26-30 (2003). (Pubitemid 36396144)
    • (2003) Revista Brasileira de Psiquiatria , vol.25 , Issue.1 , pp. 26-30
    • Buchain, P.C.1    Vizzotto, A.D.B.2    Neto, J.H.3    Elkis, H.4
  • 243
    • 20444382433 scopus 로고    scopus 로고
    • The combined use of electroconvulsive therapy and antipsychotics in patients with schizophrenia
    • DOI 10.1097/01.yct.0000165500.60784.05
    • Braga RJ, Petrides G. The combined use of electroconvulsive therapy and antipsychotics in patients with schizophrenia. J. ECT 21(2), 75-83 (2005). (Pubitemid 40800031)
    • (2005) Journal of ECT , vol.21 , Issue.2 , pp. 75-83
    • Braga, R.J.1    Petrides, G.2
  • 244
    • 77951029973 scopus 로고    scopus 로고
    • Repetitive transcranial magnetic stimulation for negative symptoms of schizophrenia: Review and meta-analysis
    • Dlabac-de Lange JJ, Knegtering R, Aleman A. Repetitive transcranial magnetic stimulation for negative symptoms of schizophrenia: review and meta-analysis. J. Clin. Psychiatry 71(4), 411-418 (2010).
    • (2010) J. Clin. Psychiatry , vol.71 , Issue.4 , pp. 411-418
    • Dlabac-De Lange, J.J.1    Knegtering, R.2    Aleman, A.3
  • 245
    • 60249097465 scopus 로고    scopus 로고
    • Meta-analysis of the effects of repetitive transcranial magnetic stimulation (rTMS) on negative and positive symptoms in schizophrenia
    • Freitas C, Fregni F, Pascual-Leone A. Meta-analysis of the effects of repetitive transcranial magnetic stimulation (rTMS) on negative and positive symptoms in schizophrenia. Schizophr. Res. 108(1-3), 11-24 (2009).
    • (2009) Schizophr. Res. , vol.108 , Issue.1-3 , pp. 11-24
    • Freitas, C.1    Fregni, F.2    Pascual-Leone, A.3
  • 246
    • 37849188208 scopus 로고    scopus 로고
    • Treatment resistance in schizophrenia: The role of alternative therapies
    • 37
    • Greenberg WM. Treatment resistance in schizophrenia: the role of alternative therapies. Psychiatric Times 23(11), 37, 40-42 (2006).
    • (2006) Psychiatric Times , vol.23 , Issue.11 , pp. 40-42
    • Greenberg, W.M.1
  • 247
    • 77949659512 scopus 로고    scopus 로고
    • Review and meta-analysis of usage of ginkgo as an adjunct therapy in chronic schizophrenia
    • Singh V, Singh SP, Chan K. Review and meta-analysis of usage of ginkgo as an adjunct therapy in chronic schizophrenia. Int. J. Neuropsychopharmacol. 13(2), 257-271 (2010).
    • (2010) Int. J. Neuropsychopharmacol. , vol.13 , Issue.2 , pp. 257-271
    • Singh, V.1    Singh, S.P.2    Chan, K.3
  • 248
    • 67749114569 scopus 로고    scopus 로고
    • Yi-gan san as adjunctive therapy for treatment-resistant schizophrenia: An open-label study
    • Miyaoka T, Furuya M, Yasuda H et al. Yi-gan san as adjunctive therapy for treatment-resistant schizophrenia: an open-label study. Clin. Neuropharmacol. 32(1), 6-9 (2009).
    • (2009) Clin. Neuropharmacol. , vol.32 , Issue.1 , pp. 6-9
    • Miyaoka, T.1    Furuya, M.2    Yasuda, H.3
  • 249
    • 0033062010 scopus 로고    scopus 로고
    • Megavitamin and dietary treatment in schizophrenia: A randomised, controlled trial
    • DOI 10.1046/j.1440-1614.1999.00527.x
    • Vaughan K, McConaghy N. Megavitamin and dietary treatment in schizophrenia: a randomised, controlled trial. Aust. NZ J. Psychiatry 33(1), 84-88 (1999). (Pubitemid 29121904)
    • (1999) Australian and New Zealand Journal of Psychiatry , vol.33 , Issue.1 , pp. 84-88
    • Vaughan, K.1    McConaghy, N.2
  • 250
    • 70349958161 scopus 로고    scopus 로고
    • Acupuncture for schizophrenia: A systematic review and meta-analysis
    • Lee MS, Shin BC, Ronan P, Ernst E. Acupuncture for schizophrenia: a systematic review and meta-analysis. Int. J. Clin. Pract. 63(11), 1622-1633 (2009).
    • (2009) Int. J. Clin. Pract. , vol.63 , Issue.11 , pp. 1622-1633
    • Lee, M.S.1    Shin, B.C.2    Ronan, P.3    Ernst, E.4
  • 251
    • 34547114455 scopus 로고    scopus 로고
    • Yoga therapy as an add-on treatment in the management of patients with schizophrenia - A randomized controlled trial
    • DOI 10.1111/j.1600-0447.2007.01032.x
    • Duraiswamy G, Thirthalli J, Nagendra HR, Gangadhar BN. Yoga therapy as an add-on treatment in the management of patients with schizophrenia-a randomized controlled trial. Acta Psychiatr. Scand. 116(3), 226-232 (2007). (Pubitemid 47106661)
    • (2007) Acta Psychiatrica Scandinavica , vol.116 , Issue.3 , pp. 226-232
    • Duraiswamy, G.1    Thirthalli, J.2    Nagendra, H.R.3    Gangadhar, B.N.4
  • 252
    • 79955116386 scopus 로고    scopus 로고
    • Iloperidone, asenapine and lurasidone. A brief overview of three new second-generation antipsychotics
    • Citrome L. Iloperidone, asenapine and lurasidone. A brief overview of three new second-generation antipsychotics. Postgrad. Med. 123(2), 153-162 (2011).
    • (2011) Postgrad. Med. , vol.123 , Issue.2 , pp. 153-162
    • Citrome, L.1
  • 253
    • 77954105828 scopus 로고    scopus 로고
    • Cariprazine, an orally active D2/D3 receptor antagonist, for the potential treatment of schizophrenia, bipolar mania and depression
    • Gründer G. Cariprazine, an orally active D2/D3 receptor antagonist, for the potential treatment of schizophrenia, bipolar mania and depression. Curr. Opin. Investig. Drugs. 11(7), 823-832 (2010).
    • (2010) Curr. Opin. Investig. Drugs. , vol.11 , Issue.7 , pp. 823-832
    • Gründer, G.1
  • 255
    • 77957674463 scopus 로고    scopus 로고
    • Thinking glutamatergically: Changing concepts of schizophrenia based upon changing neurochemical models
    • Kantrowitz JT, Javitt DC. Thinking glutamatergically: changing concepts of schizophrenia based upon changing neurochemical models. Clin. Schizophr. Relat. Psychoses 4(3), 189-200 (2010).
    • (2010) Clin. Schizophr. Relat. Psychoses , vol.4 , Issue.3 , pp. 189-200
    • Kantrowitz, J.T.1    Javitt, D.C.2
  • 256
    • 34447134211 scopus 로고    scopus 로고
    • Novel therapeutics for schizophrenia: Targeting glycine modulation of NMDA glutamate receptors
    • Stahl SM. Novel therapeutics for schizophrenia: targeting glycine modulation of NMDA glutamate receptors. CNS Spectr. 12(6), 423-427 (2007). (Pubitemid 47035288)
    • (2007) CNS Spectrums , vol.12 , Issue.6 , pp. 423-427
    • Stahl, S.M.1
  • 257
    • 15944428993 scopus 로고    scopus 로고
    • Inhibition of system A-mediated glycine transport in cortical synaptosomes by therapeutic concentrations of clozapine: Implications for mechanisms of action
    • Javitt DC, Duncan L, Balla A, Sershen H. Inhibition of system A-mediated glycine transport in cortical synaptosomes by therapeutic concentrations of clozapine: implications for mechanisms of action. Mol. Psychiatry 10(3), 275-287 (2005).
    • (2005) Mol. Psychiatry , vol.10 , Issue.3 , pp. 275-287
    • Javitt, D.C.1    Duncan, L.2    Balla, A.3    Sershen, H.4
  • 258
    • 73449097085 scopus 로고    scopus 로고
    • Using oral ziprasidone effectively: The food effect and dose-response
    • Citrome L. Using oral ziprasidone effectively: the food effect and dose-response. Adv. Ther. 26(8), 739-748 (2009).
    • (2009) Adv. Ther. , vol.26 , Issue.8 , pp. 739-748
    • Citrome, L.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.